Jeffrey John Teuteberg, MD Curriculum Vitae

Home Address: Hospital Address: 1520 Shady Avenue Scaife Hall, Suite S550 Pittsburgh, PA 15217 200 Lothrop Street (412) 421-0189 Pittsburgh, PA 15213-2582 (412) 647-7168: office (412) 647-0595: fax [email protected]

Academic Appointments Current 01/15 – current Associate Professor of Medicine, Heart and Vascular Institute, Heart Failure/Transplantation, University of Pittsburgh 12/14 – current Associate Member, Starzl Transplant Institute, University of Pittsburgh 04/05 – 12/14 Assistant Professor of Medicine, Cardiovascular Institute, Heart Failure/Transplantation, University of Pittsburgh 5/05 – current Faculty member, McGowan Institute for Regenerative Medicine 12/13-current Medical Director, Advanced Heart Failure

Prior 7/04-3/05 Visiting Assistant Professor 5/11 – 12/13 Medical Director, Mechanical Circulatory Support 7/08 – 5/11 Associate Director, Cardiac Transplantation

Education 01/03-06/04 Heart Failure and Cardiac Transplantation Fellowship, Brigham and Women’s Hospital 07/02-12/02 Heart Failure and Cardiac Transplantation Fellowship, University of Chicago 01/01-06/02 Cardiovascular Fellowship, University of Chicago 01/00-12/00 Chief Medical Resident, University of Chicago 7/99-12/99 Cardiovascular Fellowship, University of Chicago 1996-1999 Internal Medicine Residency, University of Chicago 1992-1996 University of Chicago, Pritzker School of Medicine 1987-1992 The Pennsylvania State University, B.S. Biology With Honors in Exercise and Sport Science

Board Certification ABIM – Heart Failure/Cardiac Transplantation, Certified November 2010 ABIM – Cardiovascular Subspecialty, Certified November 2004 ABIM – General Internal Medicine, Certified October 2000 USMLE I, II, III Completed 1997

Medical Licensure Pennsylvania Medical License MD424387 exp 12/31/17 Permanent Illinois Medical License IL# 036-099927 exp 7/31/05

Memberships 2004-curr International Society for Heart and Lung Transplantation 2006-curr American Society of Transplantation 2004-curr American Heart Association 2004-curr American College of Cardiology 2004-curr Heart Failure Society of America

Honors and Awards 2002 Best Fellows Award Nominee, Internal Medicine Intern class 2001-2002 1999 Humanism in Medicine Award, Arnold P. Gold Foundation 1997 Third year medical student teaching award 1997 Third year medical student teaching award 1995 Alpha Omega Alpha 1992 Graduated with Honors in Exercise and Sports Science 1992 Summa Cum Laude 1992 Phi Beta Kappa 1990 Alpha Phi Epsilon 1989 Phi Kappa Phi 1988 President's Freshman Award 1987-1991 Academic Excellence Scholarship

Articles

Submitted Perberdy MA, Gluck JA, Ornato JP, Bermudez CA, Griffin RE, Vigneshwar K, Kerber ER, Lewis EF, Link MS, Miller C, Teuteberg JJ, Thiagarajan R, Weiss RM, O’Neil B. Cardiopulmonary resuscitation in adults and children with mechanical circulatory support. Circulation 2016, submitted. Deng MC, Elashoff B, Pham MX, Teuteberg JJ, Kfoury AG, Cappola TP, Kao A, Anderson AA, Cotts WG, Ewald GA, Baran DA, Shahzad K, Hiller D, Yee J, Valatine HA. Comparative utility of gene expression profiling test score variability, endomyocardial biopsy and echocardiography to predict future clinical events in heart transplant recipients. 2016, submitted.

In press Loghmanpour NA, Kormos RL, Kanwar MK, Teuteberg JJ, Murali S, Antaki JF. Utilizing Bayesian modeling to describe the spectrum of right ventricular failure following LVAD therapy. J Am Coll Cardiol HF;2016. Teuteberg JJ, Chou JC. Permanent continuous flow left ventricular assist devices for the treatment of cardiogenic shock due to acute myocardial infarction. ASAIO J. Submitted

2016 Kobashigawa J, Teuteberg J, Colvin M, Edwards L, Daun T, Luu M. Patel J, Vega JD, Meyer D. Proceedings of the AST heart allocation meeting at the American Transplant Congress, Philadelphia Pennsylvania, May 4, 2015. Clin Transplant 2016, epub. Ambardekar AV, Forde-McLean RC, Kittleson MM, Stewart GC, Palardy M, Thiboudeau JT, Devore AD, Mountis MM, Cadaret L, Teuteberg JJ, Pamboukian SV, Cantor RS, Lindenfeld J. High early event rates in patients with questionable eligibility for advanced heart failure therapies: Results from the medical arm of mechanically assisted circulatory support (MedaMACS) registry. J Heart Lung Transplant 2016, epub. Husain S, Sole A, Alexander BD, Aslam S, Avery R, Benden C, Billaud EM, Chambers D, Danzinger- Isakov L, Fedson S, Gould K, Gregson A, Grossi P, Hadjiliadis D, Hopkins P, Luong M, Marriott DJE, Monfote V, Numoz P, Pasqualotto AC, Roman A, Silviera F, Teuteberg J, Weigt S, Zaas AK, Zuckermann A, Morrissey O. The 2015 International society of heart and lung transplantation guidelines for the management of fungal infections in mechanical circulatory support and cardiothoracic transplant recipients. J Heart Lung Fail 2016;35:261-282. Teuteberg JJ, Teuteberg WG. Palliative care for patients with heart failure. Accessed 2/13/16. http://www.acc.org/Latest-in-Cardiology/Articles/2016/02/11/08/02/Palliative-Care-for-Patients-With- Heart-Failure. Jennings DL, Horn ET, Lyster H, Panos AL, Teuteberg JJ, Lehmkuhl HB, Perez A, Shullo MA. Assessing anticoagulation practice patterns in patients on durable mechanical circulatory support devices: An international survey. ASAIO J 2016;62: 28-32.

2015 Stewart GC, Kittleson MM, ‚Cowger JA, Johnson FL, Patel CB, Mountis MM, Patel PC, Rame JE, Testani J, Guglin ME, Teuetberg JJ, Stevenson LW. Who wants a left ventricular assist device for ambulatory heart failure? Early insights from the MEDAMACS screening pilot. J Heart Lung Transplant 2015;34:1620-3. Lampert BC and Teuteberg JJ. Right ventricular failure after left ventricular assist devices. J Heart Lung Transplant 2015;34:1123-1130. Teuteberg JJ, Slaughter MS, Rogers JG, Mc Gee EC, Pagani FD, Gordon R, Rame E, Acker M, Kormos RL, Salerno C, Schleeter TP, Goldstein DJ, Shin J, Starling RC, Wozniak T, Malik AS, Silvestry S, Ewald GE, Jorde UP, Naka Y, Birks E, Narjarian KB, Hathaway DR, Aaronson KD. The HVAD left ventricular assist device: Risk factors for neurologic events and preventative mitigative strategies. J Am Coll Cardiol HF 2015;3:818-28. Kiran K, Pham MX, Teuteberg JJ, Kfoury A, Deng M, Kao A, Anderson A, Cotts W, Ewald G, Baran D, Hiller D, Yee J, Valatine H. Gene expression profiling to study racial differences after heart transplantation. J Heart Lung Transplant 2015, epub. TeutebergJJ, Simon MA. Non-invasive screening for cardiac allograft vasculopathy: Go small or go home? J Heart Lung Transplant 2015;34:158-60. Woolley JR, Kormos RL, Teuteberg JJ, Bermudez CA, Bhama JK, Lockard KL, Kunz NM, Wagoner WR. Pre-operative liver dysfunction influences blood product administration and alterations in circulating hemostatic markers following left ventricular assist implantation. Eur J Cardiothorac Surg 2015:47;497-504.

2014 Teuteberg JJ, Chou JC. Mechanical circulatory support devices in acute heart failure. Crit Care Clin 2014;30:585-606. Lampert BC, Teuteberg JJ. Shullo MA, Holtz J, Smith KJ. Cost effectiveness of routine surveillance endomyocardial biopsy beyond 12 months post heart transplantation. Circ HF 2014;7:807-13. Teuteberg JJ, Chou JC. Mechanical circulatory devices in acute heart failure. Crit Care Clinic 2014;30:585-606. Chivukula S, Shullo MA, Kormos RL, Bermudez CA, McNamara DM, Teuteberg JJ. Cancer-free survival following alemtuzumab induction in heart transplantation. Transplantation Proceedings 2014;46;1481- 1488. Deng MC, Elashoff B, Pham MX, Teuteberg JJ, Kfoury AG, Starling RC, Cappola TP, Kao A, Anderson AA, Cotts WG, Ewald GA, Baran DA, Bogaev RC, Shahzad K, Hiller D, Yee J, Valatine HA. Utility of gene expression profiling score variability to predict clinical events in heart transplant recipients. Transplantation 2014;97:708-14. Jorde UP, Kushwaha SS, Tatooles AJ, Naka Y, Bhat G, Long JW, Horstmanshof DA, Kormos RL, Teuteberg JJ, Slaughter MS, Birks EJ, Farrar DJ, Park SJ. Results of the destination therapy post- FDA approval study with a continuous flow device. J Am Coll Cardiol 2014;63:1751-1757. Wooley JR, Teuteberg JJ, Bermudez CA, Bhama JK, Lockard KL, Kormos RL, Wagner WR. Temporal leukocyte profiles and granulocyte activation in pulsatile and rotary VAD patients. Artif Organs 2014;38:447-55. Holtz J, Teuteberg J. Management of aortic insufficiency in the continuous flow left ventricular assist device population. Curr Heart Fail Report 2014;11:103-11. Lampert B, Weaver S, Scanlon A, Lockard K, Allen C, Kunz N, Bermudez C, Bhama J, Shullo MA, Kormos RL. Dew MA, Teuteberg JJ. Blood pressure control in continuous flow left ventricular assist devices – efficacy and impact on adverse events. Ann Thor Surg 2014;97:139-46. Batal O, Brumberg H, Teuteberg JJ, Katz WE. Echocardiographic sizing of the left atrium of the transplanted heart. Echocardiography 2014;31:274-8.

2013 Teuteberg JJ, Stewart GC, Jessup M, Kormos RL, Sun B, Frazier OH, Naftel DC, Stevenson LW. Implant strategies change over time and impact outcomes: Insights from INTERMACS. JACC Heart Fail 2013;1:369-78. Khandhar SJ, Yamamoto H, Teuteberg JJ, Shullo MA, Bezerra HG, Costa MA, Lee JS, Marroquin OC, McNamara DM, Mulukutla SR, Catalin T. Optical coherence tomography for characterization of cardiac allograft vasculopathy after heart transplantation (OCTCAV study). J Heart Lung Transplant 2013;32:596-602. Bhama JK, Shulman J, Bermudez CA, Bansal A, Ramani R, Teuteberg JJ, Shullo M, McNamara DM, Kormos RL, Toyoda Y. Heart Transplantation for adults with congenital heart disease: Results in the modern era. J Heart Lung Transplant 2013;32:499-504. O’Shea G, Teuteberg JJ, Severyn DA. Monitoring patients with continuous flow ventricular assist devices outside of the intensive care unit: novel challenges to bedside nursing. Prog Transplant 2013;23:39- 46. Lockard KL, Allen C, Lohmann D, Severyn DA, Schaub RA, Kaufmann KE, Hodges JR, Woodhall L, Ramanathan R, Teuteberg JJ, Eckert CE, Kormos RL. Bariatric surgery for a patient with a HeartMateII left ventricular assist device for destination therapy. Prog Transplant 2013;23:28-32. Feldman D*, Pamboukian S*, Teuteberg JJ*, Lietz K, Deng M, Kaan A, Rame JE, Birks E, Hryniewicz K, Moazami N, Perry W, Sun B, Pagani FD, Morgan JA, Dickstein ML, El-Banayosy A, Goldstein D, Loebe M, Sorensen E, Strueber M, Moore S, Arabia F, Bauman ME, Buchholz HW, John R, Grady KL, Jones K, Kusne S, Massicotte MP, Mooney M, Nelson T. 2013 International Society of Heart and Lung Transplantation guidelines for mechanical circulatory support. J Heart Lung Transplant 2013;32:157-87. *co-first authors listed alphabetically. Zeevi A, Lunz J, Feingold B, Shullo M, Bermudez C, Teuteberg J, Webber S. Persistent strong anti- HLA antibody at high titer is complement binding and associated with an increased risk of antibody mediated rejection in heart transplant recipients. J Heart Lung Failure 2013;32:98-105.

2012 Aacker MA, Pagani, FD, Gattis Stough W, Mann D, Jessup M, Kormos RL, Slaughter M, Baldwin T, Stevenson L, Aaronson K, Miller L, Naftel D, Yancy C, Rogers J, Teuteberg JJ, Starling R, Griffith B, Boyce S, Westaby S, Blume E, Wearden P, Higgens R, Mack M. Statement regarding the pre and post market assessment of durable, implantable left ventricular assist devices in the United States. J Heart Lung Transplant 2012;31:1241-52. Ann Thorac Surg 2012;94:2147-58. Circ Heart Fail 2013;6 epublished Lampert B, Teuteberg JJ. Mechanical circulatory support in 2012 – raising the bar or closing the door for xenotransplantation? Xenotransplantation 2012;19:329-32. Grady KL, Stevenson LW, Pagani FD, Teuteberg JJ, Pamboukian SV, Birks E, Moore S, Kirklin JK. Beyond Survival, Standards for Assessing Function and Quality of Life with Mechanical Circulatory Support: Recommendations from INTERMACS. J Heart Lung Transplant 2012;31:1158-64. Aaronson KD, Slaughter MS, McGee E, Cotts WG, Acker MA, Jessup ML, Gregoric ID, Loyalka P, Frazier OH, Jeevandandam V, Anderson AS, Kormos RL, Teuteberg JJ, Pagani FD, Boyce S, Hathaway D, Miller LW. Use of an intrapericardial, continuous flow, centrifugal pump in patients awaiting hear transplantation. Circulation. 2012;125:3191-3200. Teuteberg JJ, Ewald GA, Adamson RM, Lietz K, Miller LW, Tatooles AJ, Kormos RL, Sundareswaran KS, Farrar DJ, Rogers JG. Risk assessment for continuous flow left ventricular assist devices: Does the destination therapy risk score work? An analysis of over 1000 patients. J Am Coll Cardiol 2012;60:44-51. Bonde P, Ku NC, Genovese EA, Bermudez CA, Bhama JK, Ciarlegio MM, Cong X, Teuteberg JJ, Kormos RL. Model for end stage liver disease predicts adverse events related to ventricular assist device therapy. Ann Thorac Surg 2012;93:1541-7. Wang Y, Simon M, Bonde P, Harris B, Teuteberg J, Kormos R, Antaki J. Prognosis of right ventricular failure in patients with left ventricular assist device based on decision tree with SMOTE. IEEE Trans Inf Technol Biomed. 2012;16:383-90. Wang Y, Simon M, Bonde P, Harris BU, Teuteberg JJ, Kormos RL, Antaki JA. Decision tree model for prognosis of right ventricular failure in patients receiving a left ventricular assist device. J Heart Lung Transplant 2012;31:140-9. Refaat M, Tanaka T, Kormos RL, McNamara DM, Teuteberg J, Winowich S, London B, Simon MA. Survival benefit of implantable cardioverter defibrillator in left ventricular assist device supported patients. J Cardiac Fail 2012;18:140-5. Khandhar SJ, Shah HV, Shullo MA, Zomak R, Navoney M, McNamara DM, Kormos RL, Toyoda Y, Teuteberg JJ. Long-term effects on renal function of dose-reduced calcineurin inhibitor and sirolimus in cardiac transplant patients. Clin Transplant 2012;26:49-9.

2011 Zahr F, Genovese E, Mathier M, Shullo MA, Lockard K, Zomak R, McNamara D, Toyoda Y, Kormos RL, Teuteberg JJ. Obese patients and mechanical circulatory support: Weight loss, adverse events, and outcomes. Ann Thorac Surg 2011;92:1420-6. Liang KV, Pike F, Argyropoulos C, Weissfeld L, Teuteberg J, Dew MA, Unruh ML. Relationship of heart failure severity to health outcomes and health-related quality of life in maintenance hemodialysis patients in the HEMO study. Am J Kidney Disease 2011;58:84-92. Singh M, Shullo M, Kormos RL, Lockard K, Zomak R, Simon MA, Bermudez C, Bhama JK, McNamara DM, Toyoda Y, Teuteberg JJ. The degree of improvement in renal function after mechanical circulatory support impacts renal function after cardiac transplantation. Ann Thorac Surg 2011;91:1348-55. Boyle AJ, Ascheim DD, Russo MJ, Kormos RL, John R, Gelijns AC, Hong KN, Parides MK, Teuteberg JJ. Clinical outcomes for continuous flow left ventricular assist device patients stratified by pre- operative INTERMACS classification. J Heart Lung Transplant 2011;30:402-407.

2010 Genovese EA, Dew MA, Teuteberg JJ, Simon MA, Bhama JK, Bermudez CA, Lockard KL, Winowich S, Kormos RL. Early adverse events as predictors of late mortality during mechanical circulatory support. J Heart Lung Transplant 2010;29:981-8. Taylor DO, Meiser B, Webber S, Baran DA, Carboni M, Dengler T, Feldman D, Frigerio M, Kfoury A, Kim D, Kobashigawa J, Shullo M, Stehlik J, Teuteberg J, Uber PA, West L, Zuckerman A. ISHLT Heart Transplant Guidelines 2010 – Task Force 2: Immunosuppression and rejection. J Heart Lung Transplant 2010;29:914-56. Lockard KL, Weimer A, O’Shea G, Driggers E, Conroy L, Teuteberg JJ, Kormos RL. The joint commission’s disease-specific care certification for destination therapy ventricular assist devices. Prog Transplant 2010;20:155-62. Cooper DCK, Teuteberg JJ. Pig heart xenotransplantation as a bridge to allotransplantation. J Heart Lung Transplant 2010;29:981-8. Shullo MA, Schonder K, Teuteberg JJ. Elevated tacrolimus levels associated with intravenous azithromycin and cefriaxone. Transplant Proc 2010;42:1870-1872. Pham MX, Teuteberg JJ, Kfoury AG, Starling RC, Deng MC, Cappola TP, Kao A, Anderson AS, Cotts WG, Ewald GA, Baran DA, Bogaev RC, Elashoff B, Baron H, Yee J, Valantine HA. Comparison of peripheral blood gene expression profiling and endomyocardial biopsy for rejection surveillance after cardiac transplantation. New Engl J Med 2010;362:99-105. Lockard KL, Weimer A, O’Shea G, Driggers E, Teuteberg JJ, Kormos RL. Ventricular assist device discharge planning. Progress in Transplantation 2010;20:1-8. Kormos RL, Teuteberg JJ, Kirklin JK, Naftel DC, Holman WL, Stevenson LW, Milano CA, Miller MA, Pagani FD, Rogers JG, Aaronson KD. Adverse event rates in patients receiving pulsatile VADs: Incidence and composition change dramatically 3 months after implant. Teuteberg JJ, Shullo M, Zomak R, Toyoda Y, McNamara DM, Bermudez C, Kormos RL, McCurry KR. Alemtuzumab prior to cardiac transplantation allows for lower intensity immunosuppression: short- term outcomes. Am J Transplant 2010; 10: 382-388. Simon MA, Primack BA, Teuteberg J, Kormos RL, Bermudez C, Toyoda Y, Shah H, Gorscan J, McNamara DM. Left ventricular remodeling and myocardial recovery on mechanical circulatory support. J Card Fail 2010; 16:99-105 Nair PK, Kormos RL, Teuteberg JJ, Mathier MA, Bermudez C, Toyoda Y, Dew MA, Simon MA. Characterization of pulmonary hemodynamic improvements with pulsatile left ventricular assist device support. J Heart Lung Transplant 2010; 29: 201-8. Bhama JK, Adusumilli P, Zaldonis D, Siegenthatler M, Bansal A, Teuteberg JJ, Toyoda Y, McCurry KR, Kormos RL. Impact of abdominal complications on outcome following mechanical circulatory support. Ann Thorac Surg 2010;89:522-8. Kormos RL, Teuteberg JJ, Pagani FD, Russell SD, Miller LW, Massey T, Milano CA, Moazami NS, Sundareswaran KS, Farrar DJ. Right ventricular failure in patients with Heartmate II continuous flow left ventricular assist device: Incidence, risk factors, and impact on outcomes. J Thoracic Cardiovasc Surg 2010;139:1316-24.

2009 Genovese EA, Dew MA, Teuteberg JJ, Simon MA, Kay J, Siegenthaler M, Bhama JK, Bermudez C, Lockard KL, Winowich S, Kormos RL. Incidence and patterns of adverse event onset during the first sixty days after ventricular assist device implantation. Ann Thorac Surg 2009;88:1162-70. Boyle AJ, Russell SD, Teuteberg JJ, Slaughter M, Moazami N, Pagani FD, Frazier OH, Heatley G, Farrar DJ. Low thromboembolism and pump thrombosis with Heartmate II LVAD: Analysis of outpatient anticoagulation. J Heart Lung Transplant 2009;28:881-7. Bhama JK, Kormos RL, Toyoda Y, Teuteberg JJ, McCurry KR, Siegenthaler MP. Clinical experience utilizing the levatronix centrimag system for temporary right ventricular mechanical support. J Heart Lung Transplant 2009;28:971-6. Holman WL, Pae W, Teuteberg J, Acker M, Naftel D, Sun B, Milano C, Kirklin JK. INTERMACS: Interval analysis of registry data. J Am Coll Surg 2009;208(5):755-61. Bhama JK, Nguyen DQ, Scolieri S, Teuteberg JJ, Toyoda Y, Kormos RL, McCurry KR, McNamara D, Bermudez CA. Surgical revascularization for cardiac allograft vasculopathy: Is it still an option? J Thorac Card Surg 2009;137:1488-92.

2008 Refaat M, McNamara D, Teuteberg J, Kormos R, McCurry K, Shullo M, Toyoda Y, Bermudez C. Successful cidofovir treatment in an adult heart transplant patient with severe adenovirus pneumonia. J Heart Lung Transplant 2008;27:699-700. Toyoda Y, Thacker J, Santos R, Nguyen D, Bhama J, Bermudez C, Kormos R, Crespo M, Pilewski J, Teuteberg J, Alvarez R, Mathier M, McNamara D, Hattler B, McCurry K. Long-term outcome of heart and heart-lung transplantation for primary pulmonary hypertension. Ann Thorac Surg 2008;86:1116-22. Teuteberg JJ, Shullo M, Zomak R, McNamara DM, McCurry K, Kormos R. An Aggressive Steroid Weaning Strategy After Cardiac Transplantation is Achievable Without The Additional Risk of Significant Rejection. Clinical Transplantation, 2008;22:730-7. Ishizawar D, Janosko KM, Teuteberg JJ, Mathier MA, Cadaret LM, , McNamara DM. The ß1-Adrenergic receptor mediates the pharmacologic interaction of the ACE D allele and ß-blockers. Clinical and Translational Science, 2008;1:151-154. Pham MX, Deng M, Kfoury AG, Teuteberg JJ, Starling RC, Valantine H. Molecular testing for long-term surveillance in heart transplant recipients: design of the invasive monitoring attenuation through gene expression (IMAGE) trial. J Heart Lung Transplant 2007:26;808-14.

2007 Tsukui H, Abla A, Teuteberg JJ, McNamara DM, Mathier M, Cadaret LM, Kormos RL. Clinical Risk Factors and Predictors of Cerebrovascular Accidents in Patients with a Ventricular Assist Device. J Thorac Cardiov Sur 2007;134:114-123.

2006 Teuteberg JJ, Lewis EF, Nohria A, Tsang SW, Fang JC, Givertz M, Jarcho JA, Mudge GH, Baughman KL, Stevenson LW. Characteristics of patients who die with heart failure and a low ejection fraction in the new millennium. Journal of Cardiac Failure 2006;12:47-53.

2005 Tsukui H, Teuteberg JJ, McNamara DM, Buchanan JR, Winowich S, Stanford E, Murali SM, Mathier MA, Cadaret LM, Kormos RL. Biventricular Assist Device Utilization for Patients with Morbid Congestive Heart Failure: A Justifiable Strategy. Circulation 2005;112(9 suppl):I65-72.

Prior Teuteberg J, DeCara JM. Visualization of the entry site of a descending thoracic aneurysm by transthoracic echocardiography. Echocardiography 2004;21:757-758. DeCara JM, Kirpatrick JN, Spencer KT, Ward RP, Teuteberg JJ, Miller KA, Kapoor A, Furlong K, Lang RM. Use of the hand-carried ultrasound device in medical school curriculum to enhance instruction of the cardiac examination. J Am Soc Echo 2003;16:513. Verdino, R, Teuteberg, J., Burke M., Kopp D., Johnson T., Lin A., Kall J., Wilber D., Successful external cardioversion of atrial fibrillation in patients referred for internal cardioversion. Clinical Cardiology 2001;24: 500-502. Verdino RJ, Teuteberg JJ, Burke MC, Kopp DE, Johnson CT, Lin AC, Kall JG, Wilber DJ. Long-term outcome following ablation of focal atrial tachycardia: influence of preexisting structural heart disease. PACE 1999;22:773.

Abstracts 2016 Teuteberg J, Budge D, Shullo M, Hall S, Kobashigawa J. Gene expression profiling score and the risk of infection in heart transplant recipients. ATC 2016. Vu A, Althouse A, Zeevi A, Teuteberg J, Shullo M. Impact of donor specific antibodies on cardiac allograft vasculopathy. ATC 2016. Osnard M, Althouse AD, Krall L, Newman C, Grabowski C, Speicher F, Zomak R, Lagazzi L, Kormos R, Shullo M, Teuteberg J. Poor Blood Pressure Control Is Independently Associated with Renal Dysfunction After Heart Transplant. ISHLT 2016. Kittleson MM, Patel CB, Cantor RS, DeVore AD, Ambardekar AV, Thibodeau JT, Cadaret LM, Pamboukian SV, Teuteberg J, Forde-McLean RC, Mountis MM, Palardy M, Stewart GC, Hamilton MA. Physician prediction of outcomes in ambulatory patients with advanced heart failure. ISHLT 2016. Lander M, Kunz K, Dunn E, Lockard K, O’Shea G, Weaver S, Schweke T, Shullo MA, Lagazzi L, Kormos RL, Teuteberg JJ. Substantial reduction in driveline infection rates with the modification of driveline dressing protocols. ISHLT 2016. Kobashigawa JA, Khush K, Teuteberg J, Song M, Grskovic M, Hiller D, Woodward R, Deljkick E, Yee J, Latif F, Sulemanjee N, Murali S. Initial analysis of the donor-derived cell-free DNA outcomes AlloMap registry (D-OAR) study in heart transplant recipients undergoing surveillance for rejection. ISHLT 2016. Lander M, Lagazzi L, Kormos RL, O’Shea G, Weaver S, Schweke T, Shullo M, Teuteberg JJ. When antibiotics are not enough: Frequency, etiology, and durability of the surgical management of driveline infections. ISHLT 2016. Vu A, Teuteberg JJ, Zeevi A, Shullo MA. The timeline of DSA after cardiac transplantation. ISHLT 2016. Kiernan MS, DeNofrio D, Pham DT, Kapur NK, Ruthazer R, Rame JE, Alturi P, Birati EY, Myers SL, Oliveira GH, Kirklin JK, Kormos RL, Pagani FD, Teuteberg J. Risk factors associated with right ventricular assist device implantation: Insights from INTERMACS. ISHLT 2016. Holtz JE, Potter AN, Lampert BC, Lagazzi L, Kormos RL, Teuteberg JJ. No pulse, no problem! Measuring blood pressure and estimating pulse pressure in centrifugal flow left ventricular assist devices. ISHLT 2016. Teuteberg JJ, Shullo MA, Berman PJ, Haglund N, Wigger MA, Ewald GA. Higher rate of hospitalization for infection and cancer than rejection in low risk heart transplant patients followed by gene expression profiling. ISHLT 2016. Nayak A, Bachman TN, Hanley-Yanez K, McTiernan C, McNamara D, Kormos RL, Hunter O, Inashvili A, Lagazzi L, Teuteberg J, Simon MA. Chemokine receptor down regulation in mechanical circulatory support patients with right ventricular failure. ISHLT 2016. Holtz JE, Potter AN, Macpherson NC, Nguyen D, Kormos RL, Teuteberg JJ, Kellum JA. Worsening renal function after ventricular assist device placement is associated with twice the risk of death over 3 years. ISHLT 2016. Teuteberg J, Kormos RL, Pagani FD, Kiernan MS, Naftel DC, Myers SL, Pamboukian SV, Kirklin JK. New definition, same old problem: Characterizing the condition of right heart failure in INTERMACS. ISHLT 2016. Stewart GC, Ambardekar AV, Kittleson MM, Palardy M, DeVore A, Thibodeau JT, Teuteberg JJ, Cadaret LM, Forde-MacLean RC, Mountis MM, Pamboukian SV, Cantor R, Xie R, Stevenson LW. A novel combined endpoint integrating quality of life can inform decisions about VAD in ambulatory advanced heart failure. ISHLT 2016. Larsen J, Dunn EM, Kunz NM, Lockard KL, Teuteberg JJ, Lagazzi L, Althouse AD, Kormos RL. Characteristics of non-compliant LVAD patients. ISHLT 2016. Teuteberg JJ, Aaronson KD, Mahr C, Richenspruner H, Krabatsch T, Patel CB, Strueber M, Kiernana MS, Zimpfer D, Jacoski MV, Schueler S Agreeing to disagree: A comparison of antiplatelet and anticoagulation management strategies at US versus international HVAD implanting centers. ISHLT 2016. Potter A, Anderson S, Teuteberg J, Kormos R, Holtz J. Log files from the HVAD: What can daily and long-term changes in flow tell us about patients? ISHLT 2016. Bachman TN, Vanderpool R, Jacus M, Nayak A, Hunter O, Inashvili A, Lagazzi L, Teuteberg J, McTiernan C, Hanley-Yanez K, McNamara D, Kormos R, Simon M. Right ventricular failure in patients with left ventricular assist devices is associated with downregulated chemokine receptors and altered right ventricular pressure waveforms. ISHLT 2016. 2015 Zeevi A, Marrari M, Bentlejewski C, Pilewski J, Morrell M, McDyer J, Shullo M, Teuteberg J, Bermudez C, Ensor C. C1q reactivity and IgG subtypes after HLA antibody removal therapy with carfilzomib in thoracic transplant recipients. ATC 2015. Teuteberg J, Shullo M, Wolff T, Prasad P, Ewald G. Clinical use of gene-expression profiling to monitor for rejection after cardiac transplantation: Which patients and when? ATC 2015. Kanwar M, Yee J, Ewald G, Murali S, Teuteberg J. Correlation of longitudinal gene-expression profiling to cytomegalovirus infection: Results from the outcomes AlloMap registry. ATC 2015. Sulemanjee N, Prasad P, Wolff T, Thohan V. Teuteberg J. Can gene-expression profiling score help explain the adverse clinical outcomes seen in gender-mismatched heart transplants? ATC 2015. Maltais S, Ewald GA, Keebler ME, Schlendorf KH, Boyce SW, Najjar SS, Pagani FD, Aaronson KD, Jeevanandam V, Milano CA, Rogers JG, Love RB, Mahr CW, Pham DT, Kiernan MS, Kormos RL, Teuteberg JJ, Silvestry SC, McGee EC, Gordon RA, Mallidi HR, Frazier OH. Update on post- approval INTERMACS registry of the HVAD system in commercial use. ISHLT 2015. Kormos RL, McCall M, Schaub RD, Lockard KL, Bermudez CA, Kunz NM, Dunn EM, Lagazzi LF, Teuteberg JJ. Device malfunction in contemporary rotary blood pumps: The relevant burden of all components. ISHLT 2015. Jennings DL, Horn E, Lyster H, Panos A, Teuteberg J, Lehmkuhl H, Wolowich W, Shullo MA. Assessing anticoagulation practice patterns in patients on durable mechanical circulatory support devices: An international survey. ISHLT 2015. Harris J, Teuteberg J, Coons J, Winder D, Shullo M. Optimal low density lipoprotein levels prevent cardiac allograft vasculopathy. ISHLT 2015. Maltais S, Aaronson KD, Teuteberg JJ, Slaughter MS, Najjar SS, Jeevanandam V, Pham DT, McGee EC, Najarian K, Kormos RL. Temporal differences in adverse event rates in patients bridged with the HeartWare left ventricular assist device. ISHLT 2015. Teuteberg J, Wolf T, Prasad P, Ewald G. Gene expression profiling to monitor for rejection – which patients are being offered this strategy? ISHLT 2015. Ambardekar AV, Forde-McLean RC, Kittleson MM, Stewart GC, Palardy M, Thibodeau JT, DeVOre D, Mountis MM, Cadaret L, Teuteberg JJ, Pamboukian SV, Cantor RS, Lindenfeld J. High early event rates in patients with questionable eligibility for advanced heart failure therapies. ISHLT 2015. Stewart GC, Mountis MM, Kittleson MM, Ambardekar AV, Palardy M, Forde-McLean RC, Thibodeau JT, Teuteberg JJ, Pamboukian SV, DeVore AD, Cadaret L, Cantor RS, Stevenson LW. Early reassessment of ambulatory advanced heart failure detects high-risk trajectories along a dynamic baseline. ISHLT 2015. Loghmanpour NA, Kormos RL, Kanwar MK, Teuteberg JJ, Murali S, Antaki JF. Modeling the spectrum of right ventricular failure (RVF) after LVAD therapy. ISHLT 2015. Bansal U, Jackson K, Winger DG, Teuteberg JJ, Bermudez C, Kormos RL, Bansal A, Bhama JK. Update on temporary mechanical circulatory support for right ventricular failure. ISHLT 2015. Rame JE, Teuteberg JJ, Birks EJ, Rogers JG, Acker MA, Birati EY, Slaughter MS, Aaronson KD, Keadley K, Pagani FD, Kormos RL. An analysis of early versus late right heart failure with an intrapericardial continuous flow LVAD. ISHLT 2015. Selby VN, Teuteberg JJ, Allen IE, Tedford RJ, Kormos RL, De Marco T. Characterization and impact of pulmonary hypertension on outcomes after left ventricular assist device implantation. ISHLT 2015.

2014 S Bansal, KR Jackson, JK Bhama, J Teuteberg, M Simon, C Bermudez, M Shullo, L Hufman, JW Hayanga, KL Lockard, RL Komos. A time-dependent model of survival for adverse event in bridge to transplant patients. ISHLT 2014. M Deng, A Kfoury, J Teuteberg, B Elashoff, D Hiller J Yee, H Valatine. Comparative utility of gene expression profiling score variability, endomyocardial biopsy and echocardiography to predict future clinical events in heart transplant recipients. ISHLT 2014 N Uriel, J Teuteberg, S Pinney, M Crespo-Leiro, S Hall, A Crumbley, M Deng, J Vanhaecke, J Stypmann, D. Hiller, PJ Arnold, J Yee, C Patel, R Starling, D Feldman. Gene expression profiling test (GEP) scores and outcomes of heart transplant with prior mechanical circulatory support: results from IMAGE and CARGOII. ISHLT 2014 JJ Teuteberg, M McNulty, J Holtz, N Kunz, K Lockard, E Dunn, C Bermudez, JK Bhama, MA Shullo, R Kormos, M Dew. Impact of mechanical support on quality of life measures over time – is there a differential response based upon indication? ISHLT 2014 SV Pamboukian, JW Baddley, JK Kirklin, RX Cantor, DC Naftel, JD Miller, JJ Teuteberg. Outcomes of mechanical circulatory support in HIV infected patients from the INTERMACS registry. ISHLT 2014 SJ Khandhar, MA Shullo, A Zeevi, C Toma, JJ Teuteberg. Relationship between anit-HLA antibodies and coronary allograft vasculopathy after heart transplantation. ISHLT 2014 JJ Teuteberg, MS Slaughter, J Rogers, E McGee, FD Pagani, R Gordon, JE Rame, M Acker, R Kormos, CT Salerno, TP Schleeter, DJ Goldstein, J Shin, RC Starling, T Wozniak, AS Malik, SC Silvestry, G Ewald, EJ Birks, KB Najarian, DR Hathaway, KD Aaronson. Impact of device design and patient management on the incidence of neurologic events after HVAD left ventricular assist device. ISHLT 2014 L Sacha, JJ Teuteberg, A Zeevi, C Bermudez, R Kormos, C Ensor, J McDyer, MA Shullo. Carfilzomib for refractory antibody mediated rejection and allosensitization in heart transplantation. ISHLT 2014 S Maltais, ME Keebler, KH Schlendorf, SW Boyce, SS Najjar, FD Paganai, KD Aarsonson, V Jeevanandam, CA Milano, J Rogers, R Love, C Mahr, D Thin Pham, M Kiernana, RL Kormos, JJ Teuteberg, SC Silvestry, G Ewald, EC McGee, R Gordon, HR Mallidi, OH Frazier. First report of the PAS INTERMACS registry of the HVAD in commercial use. ISHLT 2014 BC Lampert, JJ Teuteberg, MA Shullo, J Holtz, K Smith. Cost effectiveness of routine surveillance endomyocardial biopsy beyond 12 months post heart transplantation. ISHLT 2014 JK Bhama, MA Dew, JJ Teuteberg, JA Hayanga, L Huffman, S Bansal, M Simon, CA Bermudez, T Richards, RL Kormos. Can body mass index indentify patients at risk for right ventricular failure after LVAD placement? ISHLT 2014 RL Zhang, TJ Richards, JK Bhama, PL Sappington, SA Esper, JJ Teuteberg, R Kormos, CA Bermudez. Mortality differences between men and women following the use of extracorporeal membrane oxygenation after myocardial infarction. ISHLT 2014 CR Ensor, A Zeevi, MR Morrell, SA Yousem, J D’Cunha, JM Pilewski, C Bermudez, MA Shullo, JJ Teuteberg, JF McDyer. First experience with the novel proteasome inhibitor carfilzomib for antibody mediated rejection after lung transplantation. ISHLT 2014 MA Shullo, C Yost, T Sabatine, R Ramani, R Kormos, J Bhama, R Zomak, C Bermudez, M Mathier, JJ Teuteberg. Transplant pharmacist evaluation prior to heart transplantation uncovers medication noncompliance as a common issue. ISHLT 2014 J Holtz, MA Dew, M McNulty, K Lockard, N Kunz, E Dunn, J Bhama, C Bermudez, M Shullo, R Kormos, J Teuteberg. Impact of early major adverse events on quality of life after mechanical circulatory support. ISHLT 2014

2013 Teuteberg J, Yost C, Newman C, Grabowski C, Kormos R, McNamara D, Zomak R, Bermudez C, Shullo M. Five year survival and graft function with the clinical use of gene expression profiling for rejection surveillance. ATC 2013, oral. Teuteberg J, Zomak R, Newman C, Yost C, Grabowski C, Bermudez C, McNamara D, Kormos R, Shullo M. Graft function and transplant vasculopathy after alemtuzumab induction in cardiac transplantation: five year outcomes. ATC 2013, oral. Teuteberg J, Scanlon A, Weaver S, Zomak R, Kormos R, Bermudez C, McNamara D, Shullo M. Effect of goal tacrolimus level on renal function over five years post-transplant. ATC 2013, poster. M.M. Kittleson, G.C. Stewart, J. Cowger, C. Patel, E. Rame, J. Testani, M. Mountis, P. Patel, F. Johnson, M. Guglin, J. Teuteberg, J.A. Kobashigawa, L.W. Stevenson, M.A. Hamilton. Triage for advanced heart failure: Effect of regional wait time disparity. ISHLT 2013, poster. A. Hackmann, K. Lockard, C. Allen, N. Kunz, K. Jackson, J. Bhama, C. Bermudez, J. Teuteberg, R. Kormos. Post Discharge Non-Compliance Increases Risk of Left Ventricular Assist Device (LVAD) Malfunction but Does Not Affect Survival. ISHLT 2013, poster. U.P. Jorde, S.S. Khushwaha, A.J. Tatooles, Y. Naka, G. Bhat, J.W. Long, D. Horstmanshof, R.L. Kormos, J.J. Teuteberg, M.S. Slaughter, E.J. Birks, D.J. Farrar, S.J. Park. Two-Year Outcomes in the Destination Therapy Post-FDA-Approval Study with a Continuous Flow Left Ventricular Assist Device: A Prospective Study Using the INTERMACS Registry. ISHLT 2013, oral. C. Patel, M. Daneshmand, G.C. Stewart, M.M. Kittleson, J. Cowger, E. Rame, M. Mountis, F. Johnson, P. Patel, M. Guglin, J.J. Teuteberg, M. Drazner, J. Rogers. Clinical Characteristics and Outcomes in Patients with Mismatched Filling Pressures in Advanced Heart Failure: Looking beyond the JVP. ISHLT 2013, oral B.C. Lampert, M.A. Shullo, N. Kunz, K. Lockard, C. Allen, J. Bhama, C. Bermudez, R. Kormos, J.J. Teuteberg. Effect of Blood Pressure (BP) Control in Continuous Flow Left Ventricular Assist Devices (CF-LVAD) on Aortic Insufficiency (AI) and Neurologic Events. ISHLT 2013, oral. M.C. Deng, B. Elashoff, D. Hiller, M.X. Pham, J.J. Teuteberg, A.G. Kfoury, R.C. Starling, A. Kao, A.S. Anderson, W.G. Cotts, G.A. Ewald, D.A. Baran, J. Yee, H.A. Valantine. Utility of Gene Expression Profiling Test Score Stability To Predict Future Clinical Events in Heart Transplant Recipients. ISHLT 2013, oral. C.B. Link, R. Kormos, K. Jackson, J. Teuteberg, J. Bhama, C. Bermudez, M.A. Simon. Predicting RV Failure after LVAD Implantation: Utility of Echocardiographic Strain and Defining RV Failure. ISHLT 2013, poster. B.C. Lampert, C. Eckert, M.A. Shullo, A. Scanlon, S. Weaver, J. Bhama, C. Bermudez, R. Kormos, J.J. Teuteberg. Differential Response to Afterload in Axial and Centrifugal Continuous Flow Left Ventricular Assist Devices (CV-LVAD). ISHLT 2013, oral. J.J. Teuteberg, R. Zomak, C. Yost, C. Newman, C. Grabowski, J.K. Bhama, R.L. Kormos, D. McNamara, C. Bermudez, M.A. Shullo. Alemtuzumab Induction Facilitates Steroid-Free Immunosuppression in Human Cardiac Transplantation: Five Year Outcomes. ISHLT 2013, poster. J.J. Teuteberg, N. Kunz, C. Allen, K. Lockard, M. Simon, J.K. Bhama, C. Bermudez, M.L. McNulty, R.L. Kormos, M.A. Dew. Impact of Mechanical Support on Quality of Life Measures over Time. ISHLT 2013, oral. K. Jackson, C. McAnaney, J. Teuteberg, M.A. Dew, J. Bhama, C. Bermudez, R. Ramani, D. McNamara, R. Kormos. Impact of Early Adverse Events (AE's) on Later Mortality in Patients Supported by Continuous-Flow Ventricular Assist Devices (CF-VAD). ISHLT 2013, poster. J.J. Teuteberg, R.L. Kormos, K. Lockard, N. Kunz, C. Allen, A. Scanlon, S. Weaver, D. Hall, C. Bermudez, M.A. Shullo. Management of Anticoagulation in Patients with Mechanical Circulatory Support Using a Physician-Based Versus a Pharmacist Directed Anticoagulation Clinic-Based Strategy. ISHLT 2013, poster. G.C. Stewart, J.J. Teuteberg, M. Kittleson, J. Cowger, C. Patel, F. Johnson, M. Mountis, P. Patel, E. Rame, M. Guglin, L.W. Stevenson. INTERMACS Profiling Identifies Risk of Death or VAD among Medically-Managed Advanced Heart Failure Patients. ISHLT 2013, oral. J. Testani, G.C. Stewart, M. Kittleson, M. Mountis, C. Patel, F. Johnson, M. Guglin, J. Cowger, J. Teuteberg, J.E. Rame. Low Serum Total Cholesterol and Triglycerides Are Associated with Adverse Events in Advanced Heart Failure: The "Lipid Paradox" in MEDAMACS. ISHLT 2013, oral.

2012 Lunz J, Webber S, Shapiro R, Feingold B, Teuteberg J, Shullo M, Zeevi A. High titer HLA antibody is complement binding and associated with antibody mediated rejection risk in heart and kidney patients. ATC 2012. Chivukula S, Shullo M, Teuteberg J, Navoney M, Bermudez C, McNamara D, Kormos R. Cancer-free survival following alemtuzumab in cardiac transplantation. ATC oral abstract 2012. Khandhar SJ, Yamamoto H, Teuteberg JJ, Shullo MA, Costa MA, Bezerra HG, McNamara DM, Lee JS, Toma C. Optical coherence tomography for plaque characterization in cardiac allograft vasculopathy. ATC 2012. Teuteberg JJ, Zomak R, Navoney M, McNamara D, Bermudez C, Kormos RL, Shullo MA. Four year rates of CMV viremia and treated CMV disease for a preemptive versus prophylactic CMV strategy after cardiac transplantation. ACT 2012 oral. Shullo MA, Johnson D, Corman SL, Teuteberg JJ. Early angiotensin blockade for renal protection after heart transplantation in patients receiving calcineurin inhibitors. ATC 2012. Jorde UP, Kushwaha SS, Tatooles AJ, Naka Y, Bhat G, Long JW, Horstmanshof DA, Kormos RL, Teuteberg JJ, Slaughter MS, Birks EJ, Farrar DJ, Park SJ. Initial results of the destination therapy post-PDA-approval study with a continuous flow left ventricular assist device: a prospective study using the INTEMACS registry. ISHLT 2012, oral. Teuteberg JJ, Stewart G, Jessup M, Kormos RL, Sun B, Frazier OH, Naftel D, Stevenson L. Implant strategies for continuous flow LVAD therapy in INTERMACS – impact on outcomes and variability over time. ISHLT 2012, oral. Stewart GC, Kittleson MM, Cowger J, Patel C, Johnson F, Mountis M, Patel P, Rame E, Testani J, Guglin M, Teuteberg J, Stevenson L. High event rates in medically managed advanced heart failure patients followed at VAD centers. ISHLT 2012, oral. Lampert BC, Teuteberg JJ, Kormos RL. HeartMateII as a bridge to weight loss. ISHLT 2012. Guglin M, Stewart GC, Kittleson MM, Cowger J, Patel C, Johnson F, Mountis M, Patel P, Rame E, Testani J, Teuteberg J, Miller LW. Uric acid elevation is associated with severity of congestion in advanced heart failure. ISHLT 2012. Cotts WG, Deng MC, Elashoff B, Pham MX, Teuteberg JJ, Kfoury AG, Starling RC, Cappola TP, Kao A, Anderson AS, Ewald GA, Baran DA, Bogaev RC, Stosor V, Yee JP, Valantine HA. Corelation of cytomegalovirus (CMV) serologic status of heart transplant recipients to gene expression profiling scores and clinical outcomes: results from the IMAGE multicenter trial. ISHLT 2012. Shullo MA, Zomak R, Grabowski C, Navoney M, McNamara D, Bermudez C, Kormos RL, Teuteberg JJ. Rates of DMV viremia and treated CMV in patients receiving alemtuzumab induction prior to cardiac transplantation. ISHLT 2012. Kormos RL, Woolley JR, Lockard KL, Bermudez C, Bhama JK, Teuteberg JJ, Wagner WR. Temporal leukocyte profiles and granulocyte activation in LVAD recipients. ISHLT 2012. Mano A, Teuteberg JJ, Bermudez CA, Bhama JK, McNamara DM, Ramani R, Simon M, Kormos RL. Factors associated with a lack of renal recovery in patients with continuous flow LVADs. ISHLT 2012. Mano A, Gorcsan J, Teuteberg JJ, Bermudez CA, Bhama JK, McNamara DM, Ramani R, Simon MA, Kormos RL. Incidence and impact of de novo aortic insufficiency following continuous flow LVAD implantation. ISHLT 2012, oral. Eckert CE, Schaub R, Lockard K, O’Shea GC, Zaldonis JA, Kormos JA, Bermudez C, Bhama JK, Teuteberg JJ, Kormos RL. Ventricular assist device (VAD) malfunction: it’s all about the peripheral components and not the pump. ISHLT 2012, oral. Patel PC, Stewart GC, Kittleson MM, Cowger J, Johnson F, Mountis M, Patel P, Rame E, Testani J, Guglin M, Teuteberg J, Drazner MH. Patients with INTERMACS 4-7 heart failure have reduced quality of life. ISHLT 2012, oral. Teuteberg JJ, Stewart GC, Kittleson MM, Cowger J, Patel C, Johnson F, Mountis M, Patel P, Rame E, Testani J, Guglin M, Kormos RL. Prediction of events in patients with advanced heart failure: application of the seattle heart failure model to the MEDAMACS population. ISHLT 2012, oral. Bermudez CA, Rocha RV, Zaldonis DB, Bhama JK, Ramani RN, Teuteberg JJ, McNamara DM, Simon MA, Kormos RL. Outcomes with mechanical support for early primary graft dysfunction in heart transplantation. ISHLT 2012. Lampert B, Weaver S, Scanlon A, Lockard K, Allen C, Kunz N, Bermudez C, Bhama JK, Shullo M, Kormos RL, Teuteberg JJ. Blood pressure control in continuous flow left ventricular assist devices – efficacy and impact on adverse events. ISHLT 2012. Testani J, Stewart GC, Kittleson MM, Cowger J, Patel C, Johnson F, Mountis M, Patel P, Guglin M, Teuteberg J, Rame JE. Tricuspid regurgitation is a measure of right heart dysfunction and is associated with event free survival in stage D heart failure: Analysis from MEDAMACS. ISHLT 2012. Mano A, Teuteberg JJ, Bermudez CA, Bhama JK, McNamara DM, Ramani R, Simon MA, Kormos RL. The relation of body size and outcome in patients using continuous flow left ventricular assist devices. ISHLT 2012. Teuteberg JJ, Zomak R, Yost C, Newman C, Navoney M, Bhama JK, McNamara D, Bermudez C. Kormos RL, Shullo MA. Alemtuzumab induction facilitates steroid-free immunosuppression in human cardiac transplantation: four year outcomes. ISHLT 2012, oral. Khandhar SJ, Yamamato H, Teuteberg JJ, Shullo MA, Bezerra HG, Costa MA, Ramratnam M, McNamara DM, Lee JS, Marroquin OC, Mulukutla SR, Toma C. Optical coherence tomography for dection of cardiac allograft vasculopathy (OCTCAV) study. ISHLT 2012. Bhama JK, Shulma J, Bermudez CA, Bansal A, Zaldonis D, Ramani R, Teuteberg JJ, Shullo M, McNamara DM, Kormos RL, Toyoda Y. Heart transplantation for adults with congenital heart disease: results in the modern era. ISHLT 2012. Zeevi A, Feingold B, Lunz J, Teuteberg J, Shullo M, Bermudez C, Webber S. High titer donor specific HLA antibody is complement binding and associated with risk of AMR in heart transplant recipients. ISHLT 2012, oral. Stewart GC, Kittleson MM, Cowger JA, Johnson FL, Patel CB, Mountis MM, Patel P, Rame E, Guglin ME, Teuteberg JJ, Stevenson LW. Who wants an LVAD for ambulatory heart failure? HFSA 2011. Tanaka TD, Kormos RL, Sareyyupoglu B, Ramani R, Teuteberg JJ, Mathier MA, McNamara DM, Simon MA. Continuous flow left ventricular assist device support as a bridge to decision in patients with end- stage heart failure complicated by pulmonary hypertension. HFSA 2011. Teuteberg JJ, Zomak R, Navoney M, Kormos RL, Toyoda Y, McNamara DM, Shullo MA. Lower tacrolimus goal levels after routine induction therapy with alemtuzumab in cardiac transplantation: impact on renal outcomes. ATC 2011. Teuteberg JJ, Ewald G, Pham XM, Kfoury AG, Starling RC, Deng MC, Cappola TP, ao A, Anderson AS, Cotts WG, Baran DA, Yee J, Valantine HA. Routine rejection surveillance by clinical assessment and echocardiography: insights from the IMAGE trial. ATC 2011. Lunz J, Webber S, Soltys K, Shapiro R, Teuteberg J, Feingold B, Morrell M, Jelinek L. Zeevi A. Determining complement binding donor specific HLA antibody by Luminex assay – is it clinically relevant? ATC 2011. Jessup ML, Goldstein D, Ascheim DD, Teuteberg JJ, Park SJ, Naftel DC, Bonzales-Stawirski GV, Ulisney KL, Kirklin JK, Kormos RL. Risk for bleeding after MCSD implant: An analysis of 2358 patients in INTERMACS. ISHLT 2011. Sareyyupoglu B, Toyoda Y, Fujimoto K, Teuteberg JJ, Shullo MA, Zaldonis D, Bonde P, Bhama JK, Bermudez C, Kormos RL, Zeevi A. Heart transplantation in sensitized recipients, the impact of pre- transplant donor-specific antibodies on clinical outcomes. ISHLT 2011. Teuteberg JJ, Ewald G, Adamson R, Lietz K, Miller L, Tatooles A, Kormos RL, Sundareswaran K, Farrar D, Rogers J. Application of the destination therapy risk score to HeartMate II clinical trial data. ISHLT 2011. Budge D, Brunisholz KD, Wolters H, Valantine HA, Pham MX, Teuteberg JJ, Deng MC, Starling RC, Cappola TP, Koa A, Anderson AS, Cotts WG, Ewald GA, Baran DA, Bogaev RC, Yee J, Kfoury AG. Do longitudinal stable lower AlloMap scores portend better outcomes after heart transplantation? ISHLT 2011. Deng MC, Wolters H, Shahzad K, Valantine HA, Pham MX, Teuteberg JJ, Kfoury AG, Starling RC, Cappola TP, Koa A, Anderson AS, Cotts WG, Ewald GA, Baran DA, Bogaev RC, Klingler T, Baron H, Yee J, Valantine HA. Personalized clinical rejection surveillance after cardiac transplantation by longitudinal gene expression profiling. ISHLT 2011. Pham MX, Wolters H, Baran DA, Starling RC, Teuteberg JJ, Kfoury AG, Deng MC, Capolla TP, Kao A, Snderson AS, Cotts WG, Ewald GA, Bogaev RC, Shahzad K, Yee JP, Valantine HA. Incidence and predictors of late rejection after cardiac transplantation. ISHLT 2011 Teuteberg JJ, Zomak R, Navoney M, Bermudez C, Bonde P, Bhama JK, Kormos RL, McNamara DM, Toyoda Y, Shullo MA. Steroid-free immunosuppression after routine aletuzumab induction in cardiac transplantation: Three year outcomes. ISHLT 2011. Slaughter MS, Aaronson KD, Boyce S, Miller LW, McGee EC, Cotts WG, Acker MA, Jessup ML, Gregoric ID, Loyalka P, Frazier OH, Jeevanandum V, Anderson SA, Kormos RL, Teuteberg JJ, Pagani FD, Bittmas RM, Hathaway DR. HVAD BTT privotal trial and continued access program (ADVANCE): Interim report of the expanded study. ISHLT 2011. Ewald GA, Teuteberg JJ, Pham SM, Wolters H, Baran DA, Starling RC, Kfoury AG, Cappola TP, Kao A, Anderson AS, Cotts WG, Boraev RC, Scheel J, Yee JP, Deng MC, Valantine HA. Tricusipid regurgitation following orthotopic heart transplantation: Mulicenter experience from the IMAGE trial. ISHT 2011. Genovese EA, Dew MA, Teuteberg JJ, Simon MA, Bhama JK, Bonde P, Bermudez C, Toyoda Y, McNamara DM, Winowich S, Lockard KL, Kormos RL. Respiratory failure while on ventricular assive device (VAD) support has persistent consequences after cardiac transplantation. ISHLT 2011. Bermudez CA, Abarca A, Zaldonis D, Toyoda Y, Bhama JK, Bonde P, Teuteberg JJ, McNamara DM, Alvarez RJ, Kormos R. Midterm outcomes of patients undergoing durable VAD support for acute myocardial infarction complicated with cardiogenic shock. ISHLT 2011. Zeevi A, Lunz J, Teuteberg J, Feingold B, Jelinek L, Shullo M, Zaldonis D, Toyoda Y, Morrell M, Webber S. Does the determination of complement binding add to the clinical utility of donor specific antibodies detected by Luminex? ISHLT 2011. Teuteberg JJ, Rogers J, Park S, Ewald G, Tatooles A, Lietz K, Miller L, Kormos RL, Sundareswara K, Farrar D, Slaughter M. Risk Assessment for continuous flow left ventricular assist devices: Does the destination therapy risk score work? An analysis of over 600 patients. ACC 2011. Teuteberg JJ, Zomak R, Bhama J, Scanlon A, Navoney M, Bermudez C, Kormos RL, McNamara D, Toyoda Y, Shullo MA. Similar rates of rejection after routine induction with alemtuzumab versus selective use of anti-thymocyte globulin in cardiac transplantation. ATC 2010. Shullo M, Zomak R, Yost C, Rebel M, Newman C, McNamara D, Kormos RL, Toyoda Y, Teuteberg JJ. Neutropenia after alemtuzumab induction in cardiac transplantation: risk factors and affects on rejection and survival. ATC 2010. Bhama J, Shullo M, Weaver S, Zomak R, Bermudez C, McNamara D, Kormos RL, Toyoda Y, Teuteberg JJ. Low donor weight to recipient ratios in selected patients do not adverse affect post-transplant outcomes. ATC 2010. Wang Y, Teuteberg JJ, Uber B, Kormos RL, Antaki JF. Optimal identification of need for right ventricular support using cost-sensitive decision tree. Oral abstract ASAIO 2010. Genovese EA, Dew MA, Teuteberg JJ, Bermudez CA, McNamara DM, Winowich S, Weimer A, Kormos RL. Equivalent outcomes of ventricular assist device (VAD) patients by gender in the modern era of mechanical support. J Heart Lung Transplant 2010;29:S41. Cain N, Teuteberg J, Feingold B, Miller S, Quivers E, Morell V, Wearden P, Kormos R, Toyoda Y, McNamara D, Chrysostomou C, Gerard V, Webber S. Outcomes of heart transplantation for patients with systemic muscular disorders. J Heart Lung Transplant 2010;29:S71. Khandhar S, Shah H, Shullo M, Newman C, Rebel M, Yost C, Zomak S, McNamara D, Kormos R, Toyoda Y, Teuteberg J. Switch to sirolimus and dose reduced calcineurin inhibitor after cardiac transplantation is safe and results in renal stability over the ensuing three years. J Hear Lung Transplant 2010;29.S84. Shullo MA, Zomak R, Bhama JK, Bermudez C, McNamara DM, Navoney M, Kormos RL, Toyoda Y, Teuteberg J. Alemtuzumab induction facilitates steroid-free immunosuppression in human cardiac transplantation: two year outcomes. J Heart Lung Transplant 2010;29:S102. Jones R, Shullo MA, Zomak R, Newman C, Rebel M, Yost C, Navoney M, McNamara DM, Toyoda Y, Kormos RL, Teuteberg J. Lower incidence of new onset diabetes after cardiac transplantation with alemtuzumab induction. J Heart Lung Transplant 2010;29:S104. Bonde P, Zeevi A, Toyoda Y, Kormos R, Bhama J, McNamara D, Teuteberg J, Sareyyupoglu B, Horai T, Shullo M, Bermudez C. Applications of a uniform strategy of virtual cross match in heart transplantation. J Heart Lung Transplant 2010;29:S150. Bermudez C, Toyoda Y, Avila F, Mulukutla S, Marroquin O, Teuteberg J, Kormos R. Use of extracorporeal membrane oxygenation (ECMO) in patients with chronic cardiomyopathy: A word of caution. J Heart Lung Transplant 2010;29:S179. Teuteberg J, Lockard K, Hanley-Yanez K, Janosko K, Bermudez C, Bhama JK, Ramani R, Simon M, Kormos RL, McTiernan C, McNamara DM. Peripheral trascriptomes after continuous flow LVAD support: improved inflammatory signatures after one month. J Heart Lung Transplant 2010;29:S182. Sareyyupoglu B, Horai T, Bonde P, Bermudez CA, Bhama JK, Tabata S, Shigemura S, Ramani RN, Simon MA, Teuteberg JJ, Mathier MA, McNamara DM, Kormos RL, Toyoda Y. Obesity is not a risk factor for heart transplantation. J Heart Lung Transplant 2010;29:S13. Teuteberg JJ, Stewart GC, Jessup M, Kormos RL, Sun B, Frazier OH, Naftel DC, Stevenson LW. Strategies for LVAD therapy in INTERMACS: Intent rate v. event rate. J Heart Lung Transplant 2010;29:S26. Liszkowski M, Teuteberg JJ, Myers SL, Rogers JG, Starling R, Ascheim DD, Stevenson LW. INTERMACS profiles of nutrition and organ function in relation to outcomes. J Heart Lung Transplant 2010;29:S27. Pham MX, Teuteberg JJ, Kfoury AG, Starling RC, Deng MC, Cappola TP, Kao A, Anderson AS, Cotts WG, Ewalk GA, Baran DA, Boaev RC, Baron H, Yee J, Valantine HA. Comparison of gene expression profiling and endomyocardial biopsy for surveillance of acute cardiac cellular rejection: Results from the IMAGE trial. J Heart Lung Transplant 2010;29:S38. Kormos RL, Bonde P, Bermudez CA, Lockard KL, Genovese EA, Teuteberg JJ, Bhama JK, Simon MA, Yoshiya T, Tetsuya H, McNamara DM. The ventricular assist device (VAD) driveline: What is the price of living with this technology? J Heart Lung Transplant 2010;29:S89. Zymek P, Teuteberg JJ, Shullo MA, Bermudez C, Kormos RL, Bhama JK, Toyoda Y, McNamara DM. Steroid minimization is associated with improved survival in patients with diabetes after heart transplant. J Heart Lung Transplant 2010;29:S103. Horai T, Ku NC, Genovese EA, Bermudez CA, Bhama JK, Teuteberg JJ, Winowich S, Weimer A, O’Shea GC, Toyoda Y, McNamara DM, Kormos RL. Major neurological events after ventricular assist device (VAD) implantation are device specific but are also related to pre-implant factors. J Heart Lung Transplant 2010;29:S174. Teuteberg JJ, Lockard K, Hanley-Yanez K, Janosko K, DeGore L, Bermudez C, Bhama J, Ramani R, Simon M, Ishizawar D, McTiernan C, Kormos RL, McNamara DM. Peripheral transcriptomes in end-stage heart failure: Inflammatory signature pre LVAD. J Cardiac Fail 2009;15: S53. Shullo M, Zomak R, Bermudez C, Bhama J, Kormos R, Toyoda Y, McNamara D, McCurry K, Teuteberg J. Alemtuzumab induction therapy allows lower intensity maintenance immunosuppression after cardiac transplantation, but dose not result in improved renal outcomes at six months. Am J Transplant 2009;9:195. Teuteberg J, Hitchens K, Tenase C, Hidetaka H, Escheverri G, Foley L, Ye Q, Ezzelarab M, Thacker J, Zhang H, Wu Y, Boada F, Cooper DCK, Ho C. Non-invasive detection of acute cellular rejection with magnetic resonance imagine in porcine cardiac allografts. Am J Transplant 2009;9:653. Grinita AL, Bermudez C, Teuteberg JJ, Toyoda Y, Kormos R, McNamara D, George PM, Speziali G, Sabatine T, Soemake K, Moral-Pillage P, Jelink L, Lomago J, Zaldonis D, Pilewski J, McCurry KR, Zeevi A. Calculated panel reactive antibody and HLA-specific antibody strength as predictors for negative virtual crossmatch and transplantability rate in sensitized heart and lung transplant candidates. Am J Transplant 2009;9:651. Pham MX, Deng MC, Teuteberg JJ, Kfoury AG, Starling RC, Anderson A, Cappola TP, Kao AC, Cotts WG, Bogaev RC, Baran DA, Ewals GA, Baron H, Valantine HA. Invasive monitoring attenaution through Gene Expression (IMAGE) trial: Current enrollment and study progress. Am J Transplant 2009;9: 646. Lockard KL, DeGore L, Schwarm P, Winowich S, O’Shea G, Siegenthaler M, Simon M, Kormos RL, Teuteberg JJ. Lack of improvement in prealbumin at two week predicts a poor outcome after mechanical circulatory support. ISHLT 2009. Oral abstract. Bhama JK, Adusumulli P, Siegenthaler MP, Zaldonis D, Bansal A, Garcia L, Gongora E, Teuteberg JJ, Toyoda Y, Bermudez CA, Speziali G, McCurry KR, Kormos RL. Impact of abdominal complications on outcomes following mechanical circulatory support. ISHLT 2009. Boyle A, John R, Moazami N, Ewald G, Salerno C, Walsh M, Teuteberg J, Kormos R, Anayanwu A, Pinney S, Desai S, Burton N, Kirklin J, Pamboukian S, Park S, Redfield M, Ascheim DD, Parides M, Rawiel U, Moquete E, Joyce L, Gelijns A, O”Connell J, McGee E, Sun B, Feldman M, Camacho M, Zucker M. US experience with a novel centrifugal LVAD in bridge to transplant (BTT) patients. ISHLT 2009. Girnita AL, Bermudez C, Teuteberg JJ, Kormos R, Speziali G, Toyoda Y, Sabatine T, Shoemaker K, McNamara D, Lelinek L, Lomago J, Zeevi A. HLA-specific antibody strength and HLA haplotype frequency as predictors for responsiveness to desensitization protocols and transplantability rate in heart transplant patients. ISHLT 2009. Oral abstract. Kormos RL, Teuteberg JJ, Siegenthaler MP, Simon MA, Kay JJ, Genovese E, Bermudez C, Toyoda T, Lockar KL, Winowich S. Pre-VAD implant risk factors influence the onset of adverse events while on a VAD. ISHLT 2009. Oral abstract. Rayappa S, Teuteberg JJ, Siegenthaler MP, Kay J, Genovese E, Simon M, Dew MA, Bhama J, Lockard KL, Kormos RL. Pre-implant risk factos for VAD’s and VAD AE’s influences the onset of adverse events following cardiac transplantation and ultimate survival. ISHLT 2009. Kormos RL, Teuteberg JJ, Kirklin JK, NAftel DC, Stevenson LW, Milano CA, Miller MA, Pagani FD, Rogers JG, Aaronson KD. Adverse event rates in patients receiving pulsatile VADs: Incidence and composition change dramatically 3 months after implant. ISHTL 2009. Oral abstract. Teuteberg JJ, Shullo M, Zomak R, Bhama J, Toyoda Y, Bermudez C, McNamara D, Kormos RL, McCurry K. Alemtuzumab induction facilitates steroid-free immunosuppression in human cardiac transplantation – one year outcomes. ISHLT 2009. Oral abstract. Teuteberg J, Hanley-Yanez K, Pippi E, Shullo M, Bermudez C, London B, Kormos R, Toyoda Y, McNamara D. Pharmacogenetic interaction of the NFAT/ C/G polymorphism and the impact of induction therapy on freedom from significant rejection after cardiac transplantation. ISHLT 2009. Oral abstract. Shullo M, Zomak R, Yost C, Rebel M, Newman C, Bermudez C, McNamara D, Kormos RL, Teuteberg JJ. Aggressive medical therapy can control the hyperlipidemia associated with sirolimus utilization after cardiac transplantation. ISHLT 2009. Oral abstract. Boyle AJ, Moazami N, John R, Ewald GA, Anyawanu AC, Pinney SP, Desai SS, Burton NA, Teuteberg JJ, Kormos RL. The VentrAssist US pivotal bridge to cardiac transplantation trial. Late Breaking Clinic Trial ACC 2009. Boyle A, Aschiem D, Russo M, John R, Kormos R, Naka Y, Gelijns A, Hong K, Parides M, Teuteberg J, et al. LVADs for less acutely ill patients: Do current data justify the strategy? ASAIO 2008, oral presentation. Boyle A, Aschiem D, Russo M, Kormos R, John R, Naka Y, Gelijns A, Hong K, Parides M Teuteberg J, et al. LVADs for less acutely ill patients: Do current data justify the strategy? ECS 2008. Holman WL, Pae W, Teuteberg J, Acker M, Naftel D, Sun B, Milano C, Kirklin JK. INTERMACS: Interval analysis of registry data. Southern Surgical Association 11/08. Pagani FD, Stevenson LW, Ulisney KL, Jeevanandam V, Teuteberg JJ, Camacho MT, Martin T, Aaronson K, Naftel DC, Kirklin JK. Pre-implant patient triage using patient status with INTERMACS: Can we refine selection strategy for MCS? ISHLT 2008. Oral abstract. Teuteberg J, Shullo M, Zomak R, Toyoda Y, Bermudez C, McNamara D, Kormos R, McCurry K. Alemtuzumab induction facilitates steroid-free maintenance immunosuppression in human cardiac transplantation. ISHLT 2008. Oral abstract Teuteberg J, Novak J, Shullo M, Simon MA, Lockard K, Coyne J, Siegenthaler M, McCurry K, McNamara D, Kormos R. Renal dysfunction before ventricular assist impacts renal function post- transplant, despite improvements in renal function during ventricular support. ISHLT 2008. Oral abstract. Kay J, Teuteberg J, Simon MA, Siegenthaler M, Genovese EA, Bermudez C, Bhama J, Dew MA, Lockard KL, Winowich S, Kormos R. Ventricular assist device (VAD) adverse events (AE) effect not only VAD survival but subsequent survival after cardiac transplantation (CTX). ISHLT 2008. Oral abstract. Genovese L, Dew MA, Simon MA, Teuteberg J, Kay J, Siegenthaler M, Bhama J, Bermudez C, Lockard KL, Winowich S, Kormos R. Cumulative incidence and pattern of adverse events in the first 60 days post ventricular assist device implantation. ISHLT 2008. Kormos RL, Teuteberg J, Russell SD, Massey T, Feldman D, Moazami N, Farrar D, Milano C. Right ventricular failure (RVF) in patients with continuous flow left ventricular assist devices (LVAD). ISHLT 2008. Oral abstract Simon MA, Teuteberg JJ, Kormos RL, Siegenthaler M, Shah H, Gorscan J, McNamara DM. Left ventricular dimension predicts successful myocardial recovery and device explant in non-ischemic cardiomyopathy patients requiring mechanical circulatory support. ISHLT 2008. Oral abstract. Bhama JK, Kormos RL, Teuteberg JJ, Toyoda Y, Navoney MD, Shullo MA, McCurry KR, Bermudez C. Does cocaine use adversely impact outcomes following cardiac transplantation? ISHLT 2008. Oral abstract. Boyle AJ, Griffith BP, Ascheim DD, Naka Y, Teuteberg JJ, Feller ED, Lyoce LD, Mancini DM, John R, Woodard J, Moquete E, Hong KN, Parides MK, Moskowitz AJ, Gelijins A, Rose EA, Kormos RL. The ventrassist LVAD as a bridge to cardiac transplantation: results of the US feasibility trial. ISHLT 2008. Oral abstract. Brann SH, Kormos RL, McCurry KR, Toyoda Y, Teuteberg J, McNamara D, Bhama JK, Bermudez CA. Influence of the duration of ventricular assist device support on survival following heart transplantation. ISHLT 2008. Mini-oral abstract. Boyle AJ, Russell SD, Teuteberg JJ, Moazami N, Moore SA, Slaughter M, Farrar DJ, John R. Low thromboembolism and pump thrombosis potential of the Heartmate II LVAD. AHA 2007. Oral abstract. Novak J, Lockard K, Simon M, McNamara D, Toyoda Y, Bermudez C, McCurry K, Kormos R, Teuteberg J. Predictors of improvement in renal function after ventricular assist device placement. HFSA 2007. Shullo M, Shah H, Khandhar SJ, Zomak R, Yost C, Rebel M, McNamara D, McCurry K, Kormos R, Teuteberg J. Long-term change in creatinine among cardiac transplant patients with dose reduced calcineurin after the addition of sirolimus. HFSA 2007 Shullo M, Khandhar SJ, Shah H, Zomak R, Yost C, Rebel M, McNamara D, McCurry K, Kormos R, Teuteberg J. Incidence of rejection after adding sirolimus to a dose reduced calcineurin inhibitor after cardiac transplantation. HFSA 2007. Shullo M, Zomak R, Yost C, Rebel M, McNamara D, McCurry K, Kormos R, Teuteberg J. Thymoglobulin induction therapy allows early renal preservation, but does not prevent deterioration of renal function after two months. HFSA 2007. Shah AM, Simon MA, Nguyen D, Bhama J, Bermudez C, Toyoda Y, Teuteberg J, McCurry K, Siegenthaler M, Kormos R. Factors affecting post-transplant mortality in patients supported with ventricular assist devices as a bridge to transplantation. HFSA 2007 Shah AM, Simon MA, Nguyen D, Bhama J, Bermudez C, Toyoda Y, Teuteberg J, McCurry K, Siegenthaler M, Kormos R. Factors affecting early mortality in patients receiving ventricular assist devices as a bridge to transplant. HFSA 2007 Rose E, Feller E, Kormos R, Naka Y, Griffith B, Joyce L, John R, Teuteberg J, Woodard J, Rawiel U, Hong K, Moquete E, Moskowitz A, Gelijns A, Parides M, Ascheim D, Boyle A. Feasibility trial results of the VentrAssist 3rd generation LVAD for bridge to cardiac transplantation. HFSA 2007. Teuteberg J, Weaver S, Stanford E, Simon M, McNamara D, Toyoda Y, Bermudez C, McCurry K, Kormos RL. Survival and Weight Loss in the obese patient after the implantation of ventricular assist devices. Oral abstract. JHLT 2007;26:S103-104. Nguyen D, Bhama J, Bermudez C, Toyoda Y, Thacker Y, Teuteberg J, McCurry K, Kormos R. Donor age influences orthotopic heart transplant (OHTX) outcome independent of traditional risk factors. JHLT 2007;26:S227. Simon MA, Shah A, Nguyen D, Bhama J, Bermudez C, Toyoda Y, Teuteberg J, McCurry K, Kormos R. Ischemic cardiomyopathy independently predicts higher mortality after ventricular assist device implantation. JHLT 2007; 26: S91. Nguyen D, Bhama J, Bermudez C, Toyoda Y, Teuteberg J, Simon M, McKurry K, Kormos R. Evolving use of left ventricular (LVAD) vs biventricular (BiVAD) assist devices. JHLT 2007;26:S89. Teuteberg J, Shullo M, Zomak R, Yost C, Simon M, Cadaret L, Mathier M, McNamara D, Toyoda Y, McCurry K, Kormos RL. Low risk of significant rejection after cardiac transplantation beyond the first post-transplant year in patients treated with tacrolimus based immunosuppression. Oral abstract. Circulation 2006;114 (Supp II): II-534. Pande RL, Teuteberg JJ, Tsang SW, Lewis EF, Nohria A, Fang JC, Givertz M, Jarcho JA, Mudge GH, Baughman KL, Stevenson LW. Improved Survival for Class III Heart Failure in 2000: Impact of Therapies Demonstrated in a Real-life Population. Oral abstract. Circulation 2006;114 (Supp II): II- 573. Ishizawar D, Simon M, Teuteberg J, Cadaret L, Alvarez RJ, Mathier M, McNamara DM. Pharmacogenetic targeting of ACE inhibitors: Interaction of the beta-1 adrenergic Arg389Gly and G- protein Beta-3 subunit 825 T/C polymorphisms. Oral abstract. Circulation 2006;114 (Supp II): II- 442. Teuteberg J, Janosko KM, Starling R, Torre-Amione G, Dec GW, McTiernan C, McNamara DM. Gender differences in myocardial histology and gene expression in recent onset cardiomyopathy: implications for recovery. JCF 2006:12;S18. Cadaret L, Tobelmann P, Janosko KM, McTiernan C, Teuteberg J, McNamara DM. Prevalence of Microchimerism in women with dilated cardiomyopathy. JCF 2006;12:S16. Teuteberg J, Shullo M, Zomak R, Yost C, Simon M, Cadaret L, Mathier M, McNamara D, Toyoda Y, McCurry K, Kormos RL. An aggressive steroid weaning strategy after cardiac transplantation is achievable without additional risk of significant rejection. WTC 2006. Teuteberg J, Shullo M, Zomak R, Yost C, Simon M, Cadaret L, Mathier M, McNamara D, Toyoda Y, McCurry K, Kormos RL. Patients undergoing endomyocardial biopsy greater than three years after cardiac transplantation have a low incidence of rejection after biopsy. WTC 2006 Shullo M, Teuteberg J, Zomak R, Yost C, Simon M, Cadaret L, Mathier M, McNamara D, Toyoda Y, McCurry K, Kormos RL. Achieving target LDL levels is achievable using aggressive lipid management strategy after cardiac transplantation. WTC 2006. Uber BE, Antaki J, Teuteberg JJ, Kormos RL. Decision Aid for Evaluation of Risk/Benefit of RVAD for Patients Receiving LVAD. ISHLT 2006. Tsukui H, Teuteberg JJ, Winowich S, Stanford E, Weaver S, Murali S, Mathier MA, McNamara DM, Cadaret LM, Simon MA, Toyoda Y, Kormos RL. Clinical Risk Factors and Predictors of Cerebrovascular Accidents in Patients with a Ventricular Assist Device. 2006 AATS submitted. Tsukui H, Teuteberg JJ, Winowich S, Stanford E, Weaver S, Murali S, Mathier MA, McNamara DM, Cadaret LM, Simon MA, Toyoda Y, McCurry KR, Kormos RL. Preoperative renal failure does not affect outcome in bridge-to-transplantation with ventricular assist device implantation. IHSLT 2006. Tsukui H, Teuteberg JJ, Winowich S, Stanford E, Toyoda Y, Murali S, Mathier MA, McNamara DM, Cadaret LM, Simon MA, McCurry KR, Kormos RL. Clinical Predictors of Right Ventricular Failure After Left Ventricular Assist Device Implantation. STS 2005. Tsukui H, Teuteberg JJ, Abla A, Winowich S, Stanford E, Toyoda Y, Weaver S, Kormos RL. Role of infection control in reducing cerebrovascular accident with long-term circulatory support. Submitted STS 2005. Kapoor A, Michalec M, Tokarczyk T, Teuteberg JJ, Zomak R, Shullo M, Cadaret L, Mathier M, McCurry K, Kormos R, Murali S, McNamara DM. Genetic variation of calcineurin NFATC4 and risk of rejection post cardiac transplantation. AHA 2005 Simon MA, Bedi MS, Kormos RL, Teuteberg J, Murali SM, Mathier MA, Cadaret LM, Nair P, Herrernan M, Tsukui H, Winowich S, Stanford E, Carozza L, London B. Implantable cardioverter-defibrillators in ventricular assist device-supported heart failure patients bridged to cardiac transplantation. AHA 2005. Ishizawar D, Teuteberg J, Cadaret L, Mathier M, Murali S, McNamara DM. Impact of ß-Receptor Selectivity on the Pharmacogenetic Interaction of the ACE D/I Polymorphism and ß-Blockers AHA 2005 Nair PK, Simon MA, Kormos RL, Teuteberg J, McNamara D, Mathier M, Cadaret L, Tsukui H, Winowich S, Stanford E, Carozza L, Murali S. Characterization of pulmonary hemodynamic improvements with left ventricular assist device support. AHA 2005 Nair PK, Simon MA, Kormos RL, Teuteberg J, McNamara D, Mathier M, Cadaret L, Tsukui H, Winowich S, Stanford E, Carozza L, Murali S. Effect of Left Ventricular Assist Device Support on Pulmonary Hemodynamics. HFSA 2005. Kapoor A, Michalec M, Palmer E, Harbison B, Svitek M, Cararet L, Mathier M, Teuteberg J, Murali S, McNamara DM. Endothelin receptor type A G231A polymorphism modulates hemodynamics in pulmonary arterial hypertension. AHA 2005. Tsukui H, Winowich S, Stanford E, Teuteberg JJ, Kormos RL. Does a rotary pump provide full cardiac decompression and circulatory support? ASAIO 2005;51. Tsukui H, Buchanan JR, Winowich S, Patel AN, Stanford E, Carozza L, Cadaret L, Teuteberg JJ, Murali S, Mathier MA, McNamara DM, Kormos RL. Biventricular Assist Device (BiVAD) utilization for patients with morbid congestive heart failure (MCHF): A justifiable strategy. ISHLT 2004. Simon MA, Teuteberg JJ, Kormos RL, Nair P, Dew MA, Heffernan M, McNamara D, Mathier M, Cadaret L, Tsukui H, Winowich S, Stanford E, Carozza L, Murali S. Risk Factors for Poor Outcomes in Ventricular Assist Devices: The Pittsburgh Bridge to Transplant Experience. Submitted to the ISHLT 2005. Simon MA, Teuteberg JJ, Kormos RL, Nair P, Dew MA, Heffernan M, McNamara D, Mathier M, Cadaret L, Tsukui H, Winowich S, Stanford E, Carozza L, Murali S. Risk Factors for Poor Outcomes in Ventricular Assist Devices: The Pittsburgh Bridge to Transplant Experience. JACC 2005;45:S 132A. Lynch JP, Teuteberg JJ. Dynamic mitral regurgitation: an atypical presentation of recurrent acute dyspnea. J Gen Intern Med 2005:20;S1. Teuteberg JJ, Lewis EF, Nohria A, Tsang SW, Fang JC, Givertz M, Jarcho JA, Mudge GH, Baughman KL, Stevenson LW. Aggressive interventions at the end-of-life in heart failure. Submitted to the American Heart Association 2004. Teuteberg JJ, Lewis EF, Nohria A, Tsang SW, Fang JC, Givertz M, Jarcho JA, Mudge GH, Baughman KL, Stevenson LW. Twenty-first century heart failure deaths. Heart Failure Society of America 2004. Pande R, Teuteberg JJ, Lewis EF, Nohria A, Tsang SW, Fang JC, Givertz M, Jarcho JA, Mudge GH, Baughman KL, Stevenson LW. Is Clinical Compromise More Severe After Delayed Disease Progression? Heart Failure Society of America 2004. Teuteberg JJ, Tedrow U, Lewis EF, Nohria A, Tsang SW, Fang JC, Givertz M, Jarcho JA, Mudge GH, Baughman KL, Stevenson LW. Deaths from heart failure in the era of the implantable defibrillator. JACC 2004;43:S 178A. Anderson AS, Kim G, Teuteberg JJ, Kim AY, Fedson SE, Murks C, Martin-Wallace S, Raman J, Jeevandadum V. The management of acute right ventricular infarction and cardiogenic shock with right ventricular assist devices and cardiac transplantation. ISHLT 2003. Fedson SE, Anderson AS, Teuteberg JJ, Bednarz J, Kim AY, Lang RM. Doppler tissue imaging offers reliable assessment of left ventricular hemodynamics when compared with B-type natriuretic peptide levels across a range of ventricular performance. J Card Failure 2003; Suppl 1, 9: S25. Teuteberg, J., Verdino, R., Burke M., Kopp D., Johnson T., Lin A., Kall J., Wilber D., Successful external cardioversion of atrial fibrillation in patients referred for internal cardioversion. Circulation 1999;100:I-722.

Chapters Teuteberg JJ, Mathier MA, Shullo MA. Cardiac Transplantation and Circulatory Support Devices. Cardiovascular Therapeutics. Atman and Sabatine Eds. Elsevier 2013. Teuteberg JJ. Predischarge and outpatient management. Braunwald’s Mechanical Circulatory Support. Kormos and Miller Eds. Elsevier 2010. Zahr F, Teuteberg JJ. Mechanical Circulatory Support. Irwin and Rippe’s Intensive Care Medicine, 7th ed. Desai and O’Gara Eds. Lippincott Williams and Wilkins 2011. Teuteberg JJ, Teuteberg WG. Course to death in heart failure, in Supportive Care of the Cardiac Patient. Beattie and Goodlin Eds. Oxford University Press, 2008. Teuteberg JJ, Fang JC. Surgical revascularization in the management of heart failure and ischemic left ventricular dysfunction. Surgical Management of Congestive Heart Failure. Fang and Couper Eds. Humana Press Inc, Totowa, NJ. 2004.

Lectures/Teaching 2015-12 Molecular diagnostics for rejection surveillance, VAD/xplant coordinators, 1 hour 2015-07 Advanced heart failure. Fellows, 1 hour 2014-09 Advanced systolic heart failure. Fellows, 1 hour 2014-03-20 MCS 101: Cardiology CRNP/PA, 1 hour 2014-01-31 MCS 101: Echocardiography lab, 1 hour 2013-02-11 MCS Basics: Cardiology RN, CRNP, Pas, 1 hour 08/01/12 Mechanical Circulatory Support: Cardiology fellows, 1 hour 6/14/12 3/15/12 LVAD, RVAD, and ECMO: CCU lecture series. 1 hour 3/14/12 Right heart catheterization: Pre- and post-transplant coordinators, VAD coordinators, 1 hour 3/15/12 LVAD, RVAD, and ECMO: CCU lecture series. 1 hour 8/4/11 Mechanical Circulatory Support: Cardiology fellows, 1 hour 1/24/11 Cardiology fellows board review: Cardiology fellows, 1 hour 12/16/10 LVAD, RVAD, and ECMO: CCU lecture series. 1 hour 8/5/10 Mechanical Circulatory Support: Cardiology fellows, 1 hour 4/3/10 LVAD, RVAD, and ECMO: CCU lecture series. 1 hour 2/4/10 LVAD, RVAD, and ECMO: CCU lecture series. 1 hour 1/28/10 Board review: Acute heart failure: Cardiology fellows, 1 hour 1/21/10 Board review: Cardiac transplantation. Cardiology fellows, 1 hour. 10/29/09 LVAD, RVAD, and ECMO: CCU lecture series. 1 hour 8/11/09 Management of Acute Heart Failure. Medicine residents, Presbyterian, 1 hour. 8/6/09 Management of Acute Heart Failure. Medicine residents, VA, 1 hour. 5/15/09 LVAD, RVAD, and ECMO: CCU lecture series. 1 hour 5/12/09 Right heart catheterization: Pre- and post-transplant coordinators, VAD coordinators, 1 hour. 1/22/09 Heart Failure: Medicines to Machines. Cardiology fellows. 1 hour 1/21/09 Heart Failure: Medicines to Machines. CRNP, HF RN, CCU RN. 1 hour. 1/13/09 Multidisciplinary team discussion. Interprofessional health care team. 2 hours 1/7/09 Introduction to VAD service and patient care. Interprofessional health care teams. 1 hour 12/11/08 LVAD, RVAD, and ECMO. CCU lecture series. 1 hour 10/14/08 A Transplant Cardiologists Perspective. Cardiothoracic Transplant Support group 1.5 hours. 6/20/08 Mechanical Assist Devices. Fellow’s Braunwalk series. Cardiology fellows. 1 hour 5/16/08 Clinical Assessment of CHF. Fellow’s Braunwald series. Cardiology fellows, 1 hour. 3/11/08 Stress testing. Pre and post-transplant coordinators, VAD coordinators, 1 hour. 2/29/08 Pulmonary Hypertension – Natural History. 1 hour. UPMC PH Clinical Preceptorship 1/22/08 Right heart catheterization: Pre- and post-transplant coordinators, VAD coordinators, 1 hour. 10/4/07 LVAD basics: Cardiology fellows, 1 hour 2/2/07 Pulmonary Hypertension – Natural History. 1 hour. UPMC PH Clinical Preceptorship. 1/30/07 LVAD basics: Cardiology fellow, 1 hour 10/9/06 Pulmonary Hypertension – Natural History. 1 hour. UPMC PH Clinical Preceptorship. 8/24/06 Management of Congestive Heart Failure. 1 hour. VA Hospital, residents. 2/21/06 Management of Chronic Systolic Heart Failure. 1 hour. 2/06 Heartmate II and echocardiography. Echo laboratory. 1 hour. 3/2/05 Transplant Vasculopathy. Cardiology fellows. 1 hour. 12/3/04 Left Ventricular Assist Devices. NHeFT course. 1 hour. 11/23/04 LVAD basics. Cardiology fellows. 1 hour.

Research Experience Multi-center protocols Role Study Sponsor Status Study PI ASPIRING – international study assessing platelet HeartWare Protocol reactivity in patients with mechanical circulatory development support Site PI MEDAMACS NHLBI Enrollment complete Site PI HeartWare Destination Therapy HeartWare Enrollment complete Site PI REVIVE-IT/REVIVAL NHLBI Complete Site PI OAR – Gene expression profiling registry XDx Active, Steering enrolling Committee Site PI MEDAMACS – pilot trial NHLBI Completed Site PI HeartWare Bridge to Transplant Trial HeartWare Completed Site PI Invasive monitoring attenuation through gene XDx Completed expression (IMAGE) trial Site PI A Randomized Open-Label Study to Compare the Wyeth Completed Safety and Efficacy of Conversion from a Calcineurin Inhibitor to Sirolimus Versus Continued Use of a Calcineurin Inhibitor in Cardiac Transplant Recipients with Mild to Moderate Impaired Renal Function Site Co-PI Evaluation of the VentrAssist left ventricular assist Ventracor Completed device as a bridge to transplantation – Pivotal Trial Inc. Site Co-PI Evaluation of the VentrAssist left ventricular assist Ventracor Study device for the treatment of advanced heart failure – Inc. stopped Destination therapy Chair, Evaluation of the VentrAssist left ventricular assist Ventracor, Completed publications device as a bridge to transplantation – Pivotal Trial Inc. committee Site Co-PI Heartmate II LVAS pivotal study Thoratec Inc. Completed

Grant support 2014 INTERMACS Local: investigator: 10% 2014 MEDAMACS – NHLBI via University of Alabama Local primary investigator: 5% 2014-15 REVIVE-IT Local primary investigator: 10% 2012 Mechanical circulatory support in patients with HIV. Co-primary investigator: 5% (NHLBI-HV-11-16) 9/30/12-11/30/15 - $246,325 2010 Alemtuzumab and regulatory Tcells for heart transplant tolerance in monkeys Co-investigator : 4% effort. Dr. Angus Thompson and Dr. David Cooper – PIs (1U01AI1091197-01) 7/15/10-6/30/15 - $666,337 2007 Competitive Medical Research Fund - $25,000. The non-invasive detection of cardiac rejection with magnetic resonance imaging. 2006 Winter Foundation - $10,000. Non-invasive assessment of cardiac rejection by MRI.

MCS Training – MacGowan Center, UPMC EvaHeart Patient Selection 10/6/10 Niguarda Hospital, Milan, Italy 3/22/11 University of Alabama at Birmingham 11/10/11 University of Pennsylvania 11/17/11 Methodist Patient Management 10/6/10 Niguarda Hospital, Milan, Italy 3/22/11 University of Alabama at Birmingham 11/10/11 University of Pennsylvania 11/17/11 Methodist HeartWare Patient Selection 1/15/14 University of Pittsburgh, internal training 9/23/10 Instituto Mediterraneo per i Trapianti e Terapie (ISMETT) Patient Management 1/15/14 University of Pittsburgh, internal training 03/15/12 University of Pittsburgh, internal training 9/22/10 Instituto Mediterraneo per i Trapianti e Terapie (ISMETT) VentrAssist VentrAssist: A Cardiologist’s Perspective 3/11/08 University of Pennsylvania 11/16/07 University of Pennsylvania 11/7/07 Beth Israel, Newark, NJ 10/19/07 Montefiore Hospital, NY 10/12/07 University of Florida 9/28/07 University of Alabama, Birmingham 9/13/07 Methodist Hospital, Houston

Heartmate II Trial Results 2/14/13 Willis Knighton Medical Center – Shreveport, LA 8/2/12 St. Peter’s Medical Center, Robert Wood Johnson Montefiore Stonybrook University Hospital Einstein Medical Center Albany Medical Center Morristown Medical Center Maimonides Medical Center Riverside Methodist Hospital Adventist Hinsdale Covenant Center for the Heart University Hospitals Cleveland Scott & White Kaiser Santa Clara Texas Heart Institute Heart Care Specialist Medical City Dallas 5/9/12 Cincinnati Children’s Hospital 2/24/12 UPMC internal training 3/24/11 Hackensack University Medical Center Northwestern Memorial Hospital Cedars Sinai Medical Center The Methodist Hospital Seton Medical Center University of Florida Froedtert Memorial Hospital Loyola University Cleveland Clinic Patient Selection 2/15/13 Willis Knighton Medical Center – Shreveport, LA 8/2/12 St. Peter’s Medical Center, Robert Wood Johnson Montefiore Stonybrook University Hospital Einstein Medical Center Albany Medical Center Morristown Medical Center Maimonides Medical Center Riverside Methodist Hospital Adventist Hinsdale Covenant Center for the Heart University Hospitals Cleveland Scott & White Kaiser Santa Clara Texas Heart Institute Heart Care Specialist Medical City Dallas

5/9/12 Cincinnati Children’s Hospital 2/24/12 UPMC internal training 3/24/11 Hackensack University Medical Center Northwestern Memorial Hospital Cedars Sinai Medical Center The Methodist Hospital Seton Medical Center University of Florida Froedtert Memorial Hospital Loyola University Cleveland Clinic 10/28/10 Children’s Hospital, University of Pittsburgh NYU Medical Center 11/19/08 Spectrum Health, Grand Rapids, MI 6/19/08 Queen Elizabeth II Hospital (Halifax) 5/1/08 Northwestern Memorial; Baptist Little Rock; St. Luke’s (IN), Thomas Jefferson, St. Vincent’s. 3/27/08 University of Chicago, Maine Medical Center Seton Medical Center (TX)

Patient Management 2/14/13 Willis Knighton Medical Center – Shreveport, LA 8/2/12 St. Peter’s Medical Center, Robert Wood Johnson Montefiore Stonybrook University Hospital Einstein Medical Center Albany Medical Center Morristown Medical Center Maimonides Medical Center Riverside Methodist Hospital Adventist Hinsdale Covenant Center for the Heart University Hospitals Cleveland Scott & White Kaiser Santa Clara Texas Heart Institute Heart Care Specialist Medical City Dallas

5/9/12 Cincinnati Children’s Hospital 2/24/12 UPMC internal training 3/24/11 Hackensack University Medical Center Northwestern Memorial Hospital Cedars Sinai Medical Center The Methodist Hospital Seton Medical Center University of Florida Froedtert Memorial Hospital Loyola University Cleveland Clinic 10/28/10 Children’s Hospital, University of Pittsburgh NYU Medical Center 11/19/08 Spectrum Health, Grand Rapids, MI 6/20/08 Queen Elizabeth II Hospital (Halifax) 5/1/08 Northwestern Memorial; Baptist Little Rock; St. Luke’s (IN), Thomas Jefferson, St. Vincent’s. 3/27/08 University of Chicago, Maine Medical Center Seton Medical Center (TX)

Device Troubleshooting and Case Studies 5/10/12 Cincinnati Children’s Hospital 3/25/11 Hackensack University Medical Center Northwestern Memorial Hospital Cedars Sinai Medical Center The Methodist Hospital Seton Medical Center University of Florida Froedtert Memorial Hospital Loyola University Cleveland Clinic 10/28/10 Children’s Hospital, University of Pittsburgh NYU Medical Center 11/9/08 Spectrum Health, Grand Rapids, MI 6/20/08 Queen Elizabeth II Hospital (Halifax) 5/1/08 Northwestern Memorial; Baptist Little Rock; St. Luke’s (IN), Thomas Jefferson, St. Vincent’s. 3/27/08 University of Chicago, Maine Medical Center Seton Medical Center (TX)

IVAD/PVAD Patient Management 7/26/12 Vanderbilt, TN Spectrum, MI McLeod Regional, SC 2/24/12 UPMC internal training 9/29/11 Columbia, NY Children’s Medical Center, Dallas Methodist Heart Hospital Scott and White Clinic Texas Children’s Hospital Florida Hospital Weill Cornell New York Presbyterian 5/12/11 Scott and White Clinic UCLA Vanderbilt Children’s Cedars Sinai Shands Hospital 12/2/10 VA Medical Center, Washington DC Hahnemann University St. Luke’s, Kansas City 11/3/10 Tulane University Maine Medical Center Abbott Northwestern, Minneapolis Florida Hospital 7/22/10 Florida Hospital Robert Wood Johnson 7/8/10 University of Chicago Seton Medical Center, Austin TX Mount Sinai Hospital St. Luke’s, Kansas City University of Colorado Nebraska Medical Center 12/30/09 Jackson Memorial, Fl Nebraska Medical Center Orlando Regional Medical Center 12/1/08 St. Boniface Hospital, Winnipeg, Canada Carle Foundation Hospital, Champagne, IL 11/19/08 Spectrum Health, Grand Rapids, MI 8/22/08 Cleveland Clinic Cornell Medical Center Columbia-Presbyterian Mayo-Jacksonville University of Minnesota-Fairfield

Patient Selection and Pre-op Optimization 9/29/11 Columbia, NY Children’s Medical Center, Dallas Methodist Heart Hospital Scott and White Clinic Texas Children’s Hospital Florida Hospital Weill Cornell New York Presbyterian 12/1/08 St. Boniface Hospital, Winnipeg, Canada Carle Foundation Hospital, Champagne, IL

CentriMag 2015-09-10

MCS trained Centrimag Evaheart Jarvik 2000 HeartMate II HeartMate 3 HeartWare VentrAssist Syncardia TAH Thoratec IVAD/PVAD Toyobo Heart

Research committees 2016 Chair, INTERMACS RV Task Force 2016 ENDURANCE publication committee 2015- CTSN LVAD MPC II Trial Operations Committee 2014- HeartMate3 CEC 2014-16 COUNTER-HF DSMB 2009-2013 DuraHeart (Terumo Heart) BTT – AE events adjudication committee 2008-2012 Adverse Events and Adjudication – IMAC trial 2007 Chair, Publications Committee – VentrAssist Feasibility trial 2006-curr Adverse Events and Adjudication subcommittee - INTERMACS

University Committees 2013-curr Transplant Executive Counsel 2012-curr Heart transplant QAPI 2010-2011 Transplant Executive Counsel 2010-curr Cardiothoracic Transplant Quality Assurance Committee 2007-2011 IRB University of Pittsburgh 2000-2002 Internship Selection Committee 2000 Make-it-Easier Committee 2000 Pharmacy and Therapeutics Committee 2000 Quality Improvement Committee 2000 Nursing-Housestaff Committee 1998-2001 Graduate Medical Education Committee 1999-2001 Chief Resident's Council

Society Committees/Positions 2017 ISHLT: Chair, Program Committee 2016 ISHLT: MCS Taskforce 2015-c INTERMACS RV taskforce, Chair 2015 ATC: 2016 Program Committee 2015-16 ISHLT: Strategic Planning Committee 2015 ISHLT: Abstract Selection Committee 2015 ISHLT: Co-chair MCS Master’s Academy 2015 ISHLT: 2016 Program Committee, Chair for MCS symposia 2014-c AST: Chair – Thoracic COP 2014-c ISHLT: Mechanical Circulatory Support Council Operating Board 2014-c ISHLT: Executive Committee 2014-c ISHLT: Board member 2014 ISHLT: Symposium Selection Committee for 2015 Annual Meeting 2014 ISHLT: Co-Chair MCS Academy 2013 ISHLT: MCS Master’s Academy Steering committee 2013-c ISHLT: Education Committee Taskforce 2013 ISHLT: Heart Failure/Transplant Academy Steering committee 2013 ISHLT: Co-Chair MCS Academy 2013 ISHLT: Past-chair MCS committee 2012-c ATC: Thoracic COP Co-chair 2012 ISHLT: Co-Chair MCS Academy 2012 ISHLT: Chair MCS committee 2011 ISHLT: Vice Chair MCS committee 2010 Program Committee: ISHLT 2011 Meeting – Clinical cardiac transplant/heart failure

Moderator/Chaired Sessions

2016 Controversies in immunosuppression. ATC 6/13/16. 2016 It is tough to make prediction, especially about the future: Outcomes in MCS. ISHLT 4/28/16. 2016 Plenary Session. Pushing new frontiers: It’s our heritage. ISHLT 4/30/16. 2015 Peri-operative and late complications. Asia Pacific-ISHLT Joint MCS Symposia, Singapore 11/6/15. 2015 Management of RV failure and GI bleeding. Asia Pacific-ISHLT Joint MCS Symposia, Singapore 11/7/15. 2015 Immune monitoring in thoracic organ transplantation: Methods and Mechanisms. ATC 2015 2015 The pit and the pendulum: VADs, dual organs and other matters of the heart. ATC 2015 2015 Donor heart allocation meeting. ATC 2015 2015 Postoperative management strategies for enhanced clinical outcomes and pump performance throughout support. HeartWare fellow’s forum. Salt Lake City, 03/2015. 2014 Bleeding and anticoagulation. HeartWare International User’s Meeting. Frankfort, Germany, 10/2014. 2014 Making bloody sense of anticoagulation. ISHLT 2014. 2014 ISHLT MCS Master’s Academy: Moderator – Palliative Care: Involvement, referral, quality of life: Challenging cases 2014 ISHLT MCS Master’s Academy: Moderator – GI bleeding: diagnosis, management, algorithm and restarting anticoagulation 2014 ISHLT MCS Master’s Academy: Moderator – Applications of diagnostic imaging and echocardiography 2014 ISHLT MCS Core Academy: Plenary session – Patient Selection 2014 ISHLT MCS Core Academy: Moderator – Managing the Right Ventricle 2013 Percutaneous devices for advanced heart failure populations. HFSA 09/25/13. 2013 Co-chair: 1st Annual North American HeartWare User’s Meeting. 2013 Optimizing pump performance and patient management to enhance clinical outcomes. 1st Annual North American HeartWare User’s Meeting. 2013 What is new in xenotransplantation. ISHLT 2013. 2013 MCS reimbursement. ISHLT 2013 2012 MCS reimbursement. ISHLT 2012. 2011 Concurrent session 18: Outcomes and complications after cardiac transplantation. 2011 Pre-meeting symposium: When does “less sick” = “sick enough” for MCS. ISHLT 2011 Sunrise symposium: Waiting in the wings – advanced heart failure. ISHLT 2010 Sunrise Symposium: Heart-Kidney Transplantation. ATC 5/3/10. 2010 Concurrent Session 8: Life after Heart Transplantation: Immune and Nonimmune Considerations. ATC 5/2/10. 2009 From Controversy to Consensus in Cardiovascular Care: Another Case of Pulmonary Hyertension on Echo: Should We Care? 6/20/09. 2009 ISHLT: Novel Technologies and Therapies in Heart Failure. 4/25/09. 2007 How to Optimize Treatment in Complex Patients. Annual Pittsburgh Symposium on Heart Failure and Pulmonary Hypertension. May 2007. 2005 Clinical Issues in Heart Failure II. Annual Pittsburgh Symposium on Heart Failure and Pulmonary Hypertension. February, 2005.

Editorial Boards 2009-curr Journal of Cardiac Failure 2016-curr Journal of Heart and Lung Transplantation

Reviewer 2012 American College of Cardiology – abstract reviewer 2011- Annals of Thoracic Surgery 2010- American Journal of Transplantation 2010 American College of Cardiology – abstract reviewer 2009-10 American Transplant Congress: Co-chair of all heart abstracts 2008-Cur American Transplant Congress – abstract reviewer 2011-curr Journal of Heart and Lung Transplantation 2008-Cur International Society of Heart and Lung Transplantation – abstract reviewer 2008-Cur Circulation 2009-Cur Circulation: HF 2006-curr Journal of the American College of Cardiology 2005 American College of Cardiology – abstract reviewer 2005-Cur Journal of Cardiac Failure 2005-08 American Board of Internal Medicine - Cardiology

Medical Advisory Board 2016 Acorda Therapeutics 2014 CareDx 2013-curr HeartWare 2013-curr AbioMed 2006 XDx 2007 United Therapeutics

Consulting 2010 Acorda Therapeutics 2008 Thoratec 2006-curr Xdx 2007 United Therapeutics 2009 Vital Engineering – Vanderbilt University VAD program

Presentations 1. Mechanical circulatory support for advanced heart failure: How sick is sick enough? UCLA Cardiology Grand Rounds. 8/8/16. 2. Less sick patients: The future of MCS? Combined St. Paul’s and Vancouver General Cardiology Grand Rounds. 7/7/16. 3. Pearls for patient management. 7/6/16 Vancouver, Canada. 4. Patient management with the HVAD left ventricular assist device. Hartford Hospital 6/7/16. 5. Meeting the challenges of medical management in the LVAD patient: Hypertension and anticoagulation. Optum’s History of Transplant Excellence. Pittsburgh 5/19/16. 6. Gene expression profiling for the non-invasive detection of rejection: Where are we in 2016? Integris Baptist Hospital 5/17/16. 7. Basic pathophysiology of cardiac failure in adults. UPMC ECMO course 5/11/16. 8. INTERMACS 4-7: The time is now (pro). ISHLT 4/27/16. 9. Real-time HVAD monitoring. ISHLT 4/27/16. 10. Gene-expression profiling for the non-invasive detection of rejection. Canadian Cardiac Transplant Network, 4/27/16. 11. Destination therapy in 2016: Where are we now? Cigna National Transplant Coordinator meeting 4/16/16. 12. Determining candidacy for DT VAD or transplant in the setting of cardiogenic shock. ACC 4/4/16. 13. Real time tools for patient management. ACC 4/3/16. 14. Real time tools for patient management. ACC 4/2/16. 15. Antiplatelet therapy and testing in VAD patients: What we know today. HeartWare cardiology meeting on antiplatelet therapy. Chicago 4/1/16. 16. Waveforms and logfiles: tools for clinical management and early mitigation of pump complications. HeartWare Fellow’s Meeting, Boston 3/19/16. 17. Waveform and log file workshop. HeartWare Fellow’s Meeting, Boston, 3/19/16. 18. Pearls for patient management. NYC Heart Failure Cardiology meeting. 3/14/16. 19. Mechanical circulatory support: Where are we in 2016? OSU cardiology grand rounds. 2/16/16. 20. Stroke and continuous-flow left ventricular assist devices. Rochester University. 2/1/16. 21. Pearls for patient management, enhanced pump function, and adverse event mitigation. Rochester University. 2/1/16. 22. Mechanical circulatory support: Where are we in 2016? UPMC Shadyside Medicine Grand Rounds. 1/28/16. 23. Carcinogenic shock therapy: Surgical or percutaneous approach? UCARS, Salt Lake City, Utah. 1/15/16. 24. When is the timing right for LVAD referral? Newcastle, England. 12/11/15. 25. Pearls for patient management, enhanced pump function, and adverse event mitigation. Northeast regional surgical meeting, Boston. 11/30/15. 26. Mechanical circulatory support in 2015: Timing of implantation. 5th Chilean Transplant Congress, Vina del Mar, Chile. 11/19/15. 27. Molecular diagnostics for rejection surveillance. 5th Chilean Transplant Congress, Cardiothoracic Plenary Talk, Vina del Mar, Chile. 11/19/15. 28. Pump thrombosis: medical versus surgical treatment. Asia Pacific-ISHLT Joint MCS Symposia, Singapore 11/7/15. 29. Post-op management and challenges. Asia Pacific-ISHLT Joint MCS Symposia, Singapore 11/6/15. 30. Management options for aortic regurgitation in the VAD patient. Asia Pacific-ISHLT Joint MCS Symposia, Singapore 11/6/15. 31. HVAD pump waveforms and log files: further analysis and applications. Canadian HVAD user’s meeting, Toronto. 10/23/15. 32. Pearls for patient management, enhanced pump function, and adverse event mitigation. Canadian HVAD user’s meeting, Toronto. 10/23/15. 33. Emergency management of VAD patients: Neurolovascular events. HFSA 09/28/15. 34. MCS as a means to evaluate adherence: expensive test or justifiable alternative?. HFSA 09/26/15. 35. Waveforms and log files. HeartWare Fellow’s Forum, Washington DC, 09/25/15. 36. Pump management: Correlating pump function with cardiac function. North American VAD Coordinator’s forum. Washington DC, 09/24/15 37. Acute cardiogenic shock: indications for CentriMag support. 09/10/15. 38. Selecting adult patients for ECMO. Children’s Hospital ECMO course. 08/28/15. 39. Non-invasive assessment of rejection: Bench to bedside and back again. Memphis 08/2015. 40. Mechanical circulatory support in 2015: Which patients and when? UCLA Cardiology Grand Rounds 07/2015. 41. Non-invasive assessment of rejection: Bench to bedside and back again. San Diego for UCSD and Sharps, 07/2015. 42. Setting a vision for VAD therapy. Philadelphia, 07/2015. 43. Surgeon, Cardiologist, and VAD Coordinator Tag Teal. ASAIO 6/2015. 44. Mechanical circulatory support: Which patients and when. UPMC Altoona Cardiology, 05/2015. 45. Risk mitigation with medical therapy in the HVAD. ISHLT 04/2015 46. Waveforms and logfiles: What have we observed? HeartWare global advisory board, 03/2015. 47. Clinical practices worldwide: results of the global anticoagulation and bleeding survey. HeartWare global advisory board, 03/2015. 48. Rejection surveillance after heart transplantation: Is the biopsy still the gold standard? Transplant Grand Rounds, Methodist Hospital, Houston, Tx. 05/2015. 49. What to do with the LVAD patient requiring renal replacement therapy. ACC 03/2015. 50. Waveforms and logfiles – breakout session. HeartWare fellow’s forum. Salt Lake City, 03/2015. 51. Waveforms and logfiles: Tools for clinical management and early mitigation of pump complications. HeartWare fellow’s forum. Salt Lake City, 03/2015. 52. Advanced heart failure and VAD therapy: who is the right patient and when is the right time? HeartWare fellow’s forum. Salt Lake City, 03/2015. 53. Integration of HVAD waveforms into clinical management strategies. Mayo Clinic, AZ. 02/04/2015 54. Integration of HVAD waveforms into clinical management strategies. Cardiothoracic Grand Rounds, University of Arizona. 02/04/2015 55. Perspective on the HVAD in heart failure medicine. HeartWare International Sales Meeting. Miami 01/2015. 56. HVAD patient management and 05/risk reduction. Indiana University. 12/2014. 57. RV failure: Treatment and the device continuum. HeartWare West Coast Physician Forum. San Diego, 11/2014. 58. Waveforms and logfiles: Tools for clinical management and early mitigation of pump complications. HeartWare Fellows Forum, Boston, 11/2014. 59. Waveform case reviews. HeartWare Fellows Forum, Boston, 11/2014. 60. Who needs long-term MCS and what is the optimal timing of implantation? Heart Failure Clinician Forum, Istanbul, Turkey. 11/2014. 61. The role of cardiologists in MCS programs in the US. Istanbul, Turkey. 11/2014. 62. Mechanical circulatory support in 2014: At a cross road? Grand Rounds, University of Colorado 11/14. 63. Beyond the biopsy: Non-invasive graft surveillance with gene expression profiling in cardiac transplantation. IPTN, Pittsburgh 11/2014. 64. Clinical experience with the HeartWare ventricular assist system: US experience. HeartWare International User’s Meeting. Frankfort, Germany, 10/2014. 65. Clinical utility of HVAD waveforms and logfiles. HeartWare International User’s Meeting. Frankfort, Germany, 10/2014. 66. From implantation to transplantation. CareDx advisory board. Chicago, 10/14. 67. Continuous flow devices in an era of choice: Outcomes, timing of implant, and patient management with the HVAD. University of Miami 09/2014 68. Which patients and when? UPMC outreach 09/2014 69. Timing of mechanical circulatory support: which patients and when? UPMC outreach 09/2014. 70. Trends and treatment options for LVAD thrombosis: Is there a difference between continuous flow LVADs? HFSA 09/2014 71. LVAD v. BiVAD v. TAH: Who, what, where, when and why? HFSA 09/2014 72. Acute management of cardiogenic shock with peripherally implanted devices: Centrimag. HFSA 09/2014 73. Bridge or destination therapy: Managing the bridge to decision patient. HFSA 09/2014. 74. VAD complications: diagnosis, prevention and treatment. HFSA 09/2014 75. Blood pressure management in the continuous flow LVAD patient. HeartWare Clinician Forum, Chicago, 09/14. 76. Clinical experience with the HVAD system. HeartWare Advisory Board Meeting, Boston 0- 6/2014. 77. Beyond the biopsy: Non-invasive graft surveillance with gene expression profiling in cardiac transplantation. Transplant Grand Rounds. UPMC 2014/06/28. 78. ADHF: Crash and burn – percutaneous tools for severe decompensation, ISHLT Heart Failure/Transplant Academy 04/09/2014 79. Patient Selection and Timing, ISHLT Heart Failure/Transplant Academy 04/09/2014 80. INTERMACS profiles 4-7: ISHLT MCS Master’s Academy 04/08/2014 81. When patients should be referred for MCS. ISHLT MCS Core Academy 04/07/2014 82. Assessing and optimizing RV function: ISHLT MCS Core Academy 04/07/2014 83. BP management and CF LVADs. ICCAC webinar. 5/7/14. 84. Continuous flow VADs in an era of choice. University of Colorado 3/18/14. 85. Using HVAD and optimizing outcomes. Ft. Wayne Indiana 2/6/14. 86. Current indications for mechanical support: Implications of the recent NCD. Legislative roundtable briefing, sponsored by Rep. Larry Bucshon, IN. 2/3/14. 87. Mechanical circulatory support: before inotropy? Cardiology Grand Rounds, Robert Wood Johnson, 01/21/14. 88. Long-term management of mechanical circulatory support. Ochsner Heart Failure Grand Rounds. 11/05/13. 89. Mechanical Circulatory Support: State of the technology in 2013: CUORE, 25th International Cardiology Symposium. Buenos Aires, Argentina. 10/17/13. 90. Advanced heart failure: Options for therapy: CUORE, 25th International Cardiology Symposium. Buenos Aires, Argentina. 10/17/13. 91. MCS in 2013: IN whom and when? Shadyside hospital medicine grand rounds. 10/10/13. 92. Risk stratification of recipients and impact of VADs on post-transplant risk. XDx MAB 09/30/13. 93. Acute management of cardiogenic shock with percutaneous devices: ECMO. HFSA 09/23/13. 94. Pulmonary hypertension and left heart disease. Pulmonary Grand Rounds. INOVA Fairfax. 09/18/13. 95. MCS in 2013: IN whom and when? WVU Cardiology Grand Rounds. 09/13/13. 96. Optimizing pump performance and patient management to enhance clinical outcomes. 1st North American HeartWare User’s Meeting 8/26/13. 97. Acute heart failure. UPMC Department of Medicine Grand Rounds 8/16/13. 98. Newer immunosuppressants in cardiac transplantation. Vanderbilt University – Vanderbilt Heart Failure Summit 8/9/13. 99. Refresher course on indications and utility of chronic VAD therapy for CHF. Shadyside Hospital 8/7/13. 100. RV Assessment and prediction. 2013 ISHLT Annual Meeting, 04/23/13. 101. How to combine a career in research with clinical practice. Dean’s Summer Research Program. 07/18/2103. 102. Patient selection and management of the HVAD. Medical College of Wisconsin. 06/06/13 103. Management of blood pressure in the VAD patient: The University of Pittsburgh Experience. 05/10/13. HeartWare advisory board. 104. HVAD Pump flow, speed, and BP: The University of Pittsburgh Experience. Montreal, Canada. 04/24/13 105. Outpatient VAD management. Hamot HF group. 1/24/13. 106. DT: Who is a candidate in 2012? UPMC webcast for Cigna. 8/30/12. 107. Diagnosis and management of heart failure. University of Pittsburgh, Department of Medicine Grand Rounds. 7/20/12. 108. Induction therapy revisited: Has alemtuzumab made a difference? ATC 6/4/12. 109. DT: Who is a candidate in 2012?. UPMC Hamot Medical Center. 5/31/12. 110. GI bleeding: what is the optimal strategy for diagnosis and management? ISHLT 4/8/12. 111. Welcome address and ISHLT MCS guideline review. ISHLT Master’s Academy, ISHLT 4/17/12. 112. BTT v. DT – Is there a difference? ACC 03/26/12 113. From shock to recovery or bridge to transplantation: Role of percutaneous VADs and other support devices. ACC 03/24/12. 114. Diagnosis and management of heart failure. University of Pittsburgh, Shadyside Hospital Department of Medicine Grand Rounds. 10/20/11. 115. MCS basics. University of Pittsburgh Catheterization Laboratory Conference. 10/11/11. 116. Care of the post-cardiac transplant patient. Cardiology Grand Rounds, Westchester Medical Center, Valhalla, NY 9/27/11. 117. Bleeding with LVADs. HFSA 2011 invited lecture 9/20/11. 118. Establishing a common indication for long-term support for VAD therapy. STS VAD development and clinical evaluation in the US. 9/16/11. 119. Non-invasive assessment of continuous flow mechanical support. HeartWare Cardiology User’s Meeting. 9/12/11. 120. Diagnosis and management of heart failure. University of Pittsburgh, Department of Medicine Grand Rounds. 8/5/11. 121. ECMO for cardiogenic shock: When and in whom? Seton Medical Center, Austin, TX. 7/21/11. 122. Care of the post-cardiac transplant patient. Medical Grand Rounds, Trinity Medical Center, Rock Island, Il. 7/19/11. 123. LV mechanical assistance: State of the art and future directions. University of Pittsburgh Cardiology Grand Rounds. 6/28/11. 124. BTT, DT, BTC, BTR: Where are with long-term support? Gordon conference, 6/15/11. 125. Pulmonary hypertension: etiology, diagnosis, and treatment. Internal Medicine Grand Rounds, Vassar Brothers Medical Center, Poughkeepsie, NY, 6/8/11. 126. Can survival with VAD be as good as transplant? ATC 5/4/11 127. C1q: A new tool for deciding when to transplant, when to biopsy, and when to treat the sensitized patient pre and post-transplant: The clinical perspective 4/16/11 128. Is hepatitis C a contra-indication for thoracic transplantation? ISHLT, San Diego, 4/16/11. 129. Referral for Mechanical Support in 2011: How sick is sick enough? ACC, New Orleans. 4/4/11. 130. Medicine to Machines. Cardiology/Cardiothoracic Transplant Rounds. ISMETT, Palermo, Italy. 1/17/11. 131. Emerging strategies for non-invasive diagnosis of cardiac allograft rejection. AST podcast 12/29/10. 132. Advanced Heart Failure – Timing to referral for VAD or transplant. Seton Heart Specialty Care and Transplant Center. Austin TX, 10/12/10. 133. Medicines to Machines: MCS in 2010. University of Chicago Cardiology Grand Rounds. 10/8/10. 134. ISHLT 2010 Care Guidelines – Recommendations for the non-invasive monitoring of acute heart transplant rejection. National Webinar. 10/5/10. 135. Rejection Surveillance After Cardiac Transplantation in 2010: Is Biopsy Still the Gold Standard? Surgical Treatment of End-Stage Cardiopulmonary Diseases Conference. University of Pittsburgh Medical Center. 10/1/10. 136. LVAD: Destination Therapy. What is it and when is it indicated? ? Surgical Treatment of End-Stage Cardiopulmonary Diseases Conference. University of Pittsburgh Medical Center. 10/1/10. 137. Advanced Heart Failure to Cardiac Transplantation – What is new in 2010? Ohio State University: Cardiology Grand Rounds. 8/27/10. 138. Insights from the IMAGE trial. Ohio State University. 8/26/10. 139. Insights from the IMAGE trial. Henry Ford Hospital. 5/27/10. 140. VADs – Are they the ultimate weight loss machines? ISHLT 2010 4/21/10. 141. Right ventricular failure after LVAD. HeartWare Investigator’s Meeting. 4/10/10. 142. Right ventricular function after LVAD. Post-operative care breakout session. Thoratec User’s Meeting. 2/20-21/10. 143. Updates in Cardiac Transplantation 2009. Transplant Nursing Education Symposium. 12/10/09. 144. Diastolic Heart Failure. From Controversy to Consensus in Cardiovascular Care. 6/20/09. 145. Mechanical Circulatory Support: Peri-operative considerations. St. Boniface Hospital. Winnipeg, Canada. 4/8/09 146. Heartmate II: System Overview and Theory of Operation. St. Boniface Hospital. Winnipeg, Canada. 4/7/09. 147. Echocardiography rounds. St. Boniface Hospital. Winnipeg, Canada. 4/7/09 148. Echocardiography and Mechanical Circulatory Support. St. Boniface Hospital. Winnipeg, Canada. 4/7/09. 149. Standard of Care for MCS: Frequency of Follow-up. INTERMACS 3rd Annual Meeting. 3/27/09. 150. Timing of MCS: Ready for a new paradigm?. HF/PH research meeting. 3/24/09. 151. Advanced Heart Failure: Medicines to Machines. Seton Medical Center, Austin TX. 10/9/08. 152. Advanced Heart Failure: Medicines to Machines. 6th Annual Frazier-Hart Educational Symposium. 9/27/08. 153. Management of Heart Failure. Grand Rounds. University of Pittsburgh. 8/22/08 154. Advanced Heart Failure: Medicines to Machines. UPMC Passavant Medical Grand Rounds. 8/5/08. 155. Updates in Cardiac Transplantation. ITNS meeting. Pittsburgh 5/14/08. 156. Length of Stay and Quality of Life. Ventracor Investigator’s Meeting. Chicago, 5/3/08. 157. Heart Failure/Cardiac Transplantation. Your Health. WRCT, Pittsburgh. 3/26/08 158. Non-invasive detection of cardiac rejection by magnetic resonance imaging. Carnegie Mellon University, Mellon Institute. 2/27/08 159. University of Pittsburgh, Section of Palliative Care. Ask An Expert: The transition from heart failure to transplant. 10/24/07. 160. VentrAssist: A Cardiologist’s Perspective. VentrAssist Pivotal Trial Investigators Meeting. 10/6/07. 161. Allomap Molecular Expression Testing. Loyola University, Chicago, IL. 9/26/07 162. Allomap Molecular Expression Testing. St. Joseph’s Hospital, Peoria, IL. 9/11/07 163. Management of Heart Failure. Grand Rounds. University of Pittsburgh. 8/10/07 164. Allomap Molecular Expression Testing. University of Kentucky. 6/5/07. 165. Allomap Molecular Expression Testing. Fort Wayne, Indiana. 6/07 166. Advanced heart failure, VADs, and cardiac transplant. Shadyside 2 hours. 5/15/07 167. Supporting the Injured Myocardium, Mechanical Support of the Failing Ventricle. Shadyside Catheterization Laboratory. 1 hour. 4/17/07 168. Changing demographics of pulmonary hypertension. Annual Pittsburgh Symposium on Heart Failure and Pulmonary Hypertension. May, 2007. 169. CHF basics. Abiomed engineers and staff. November 2006. 170. Updates in Heart Failure 2006. Annual Pittsburgh Symposium on Heart Failure and Pulmonary Hypertension. May, 2006. 171. Cardio-renal syndrome. Annual Pittsburgh Symposium on Heart Failure and Pulmonary Hypertension. February, 2005. 172. Stevenson LW, Teuteberg J. End-of-life care for heart failure patients in the era of advanced cardiovascular medicine. Combined Harvard Palliative Care faculty seminar. October 10, 2003. 173. Post-Partum Cardiomyopathy. Section of Obstetrics and Gynecology conference. July, 2002. 174. Too close to call? External Beam Computed Tomography for the Detection of Coronary Artery Disease in Asymptomatic Patients. Internal Medicine Grand Rounds. University of Chicago. December 2000.

Additional Training 2013 PSD Physician Leadership and Management Mini-MBA Certificate Program, University of Pittsburgh 2005 Clinical Research Training Program, University of Pittsburgh 2005 Linear Regression, University of Pittsburgh 2006 Survival Analysis, University of Pittsburgh 2006 Nonparametric Statistics, University of Pittsburgh 2006 Logistic Regression, University of Pittsburgh

Additional Teaching Experience 4/1/08 Pharmacologic Treatment of Congestive Heart Failure: PBL session. 1.5 hours, MSIVs.

Harvard Medical School 2003 Cardiovascular Hemodynamics

University of Chicago 2002 Right Ventricular Dysfunction and Tricuspid Regurgitation 2002 Orientation to the Clinical Biennium: EKG Interpretation 2002 ER Approach to Arrhythmias and Conduction Disturbances 2002 Rheumatic Heart Disease, Clinical Pathophysiology, Pritzker School of Medicine 2001-2002 Third year student course: EKG Basics. Conceived, developed, taught, and administrated 2001 Orientation to the Clinical Biennium: EKG Interpretation 2000 Rheumatic Heart Disease, Clinical Pathophysiology, Pritzker School of Medicine 1996-1998 Physical diagnosis for second year medical students 1996-1998 Introduction to the Patient Interview for first year medical students 1996 Teaching assistant, Human Morphology I 1994 Teaching assistant, Human Morphology I Bedside Teaching Module 2002 University of Chicago: Becoming a Resident Teacher. 2001 University of Chicago Office of Medical Education Retreat: Teaching Skills for the Medical Educator. 2000 University of Chicago Office of Medical Education Retreat: Teaching Skills for the Medical Educator.